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1 INTRODUCTION 
1.1 The definition of pulmonary hypertension 
The first description of pulmonary hypertension (PH) was from autopsy specimens 
over a century ago by the German physician Ernst von Romberg [1]. The first clinical and 
hemodynamic study was published in 1951 by Dresdale [2]. Pulmonary hypertension is 
defined as a sustained elevation in mean pulmonary artery pressure (mPAP) of 25 mm 
Hg or more at rest, and it must be assessed by right heart catheterization. The pressure 
in a normal pulmonary artery is in the range of 14 ± 3 mm Hg with a normal upper limit 
of approximately 20 mm Hg at rest. The clinical significance of a mPAP of 21-24 mm Hg 
is unclear. People with a mPAP in this range are at risk of developing pulmonary arterial 
hypertension (PAH) and should be closely monitored. Furthermore, PH can be 
subclassified as precapillary (PAWP ≤15 mm Hg) or postcapillary (PAWP >15 mm Hg) 
according to the level of pulmonary artery wedge pressure (PAWP) [3].   
1.2 The classification of pulmonary hypertension 
Pulmonary hypertension was initially classified into primary PH and secondary PH 
based on the absence or presence of identifiable causes. With a better understanding of 
the disease, the classification of PH has gone through a series of changes based on 
mechanisms rather than associated conditions. According to the updated clinical 
classification of PH by the consensus in 5th World Symposium on Pulmonary 
Hypertension in 2013, PH was classified into five categories (Table 1, next page) that 
share similar pathophysiologic mechanisms, clinical presentations, and therapeutic 
approaches [3, 4]. 
PAH represents a subgroup of PH patients who are hemodynamically characterized 
by the presence of pre-capillary PH. These patients have a PAWP of ⩽15 mmHg and a 
pulmonary vascular resistance (PVR) of >3 Wood units (WU), without other causes of 
pre-capillary PH such as PH due to lung diseases, chronic thromboembolic pulmonary 
hypertension (CTEPH), or other rare diseases [5]. Pulmonary arterial hypertension has 
several subcategories that differ in etiology, though these categories share similar 
pathological and hemodynamic characteristics and terms of clinical management [5]. 
These pathological features include pulmonary arterial endothelial cell (EC) dysfunction, 
pulmonary artery EC and smooth muscle cell (SMC) proliferation, vasoconstriction, and 
in situ thrombosis [6, 7].  
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Table 1 Clinical classification of pulmonary hypertension 
1. Pulmonary arterial hypertension (PAH) 
1.1 Idiopathic 
1.2 Heritable 
1.2.1 BMPR2 mutation 
1.2.2 ALK1, ENG, SMAD9, CAV1 and KCNK3 mutation 
1.2.3 Unknown 
1.3 Drugs and toxins induced 
1.4 Associated with: 
1.4.1 Connective tissue disease 
1.4.2 HIV infection 
1.4.3 Portal hypertension 
1.4.4 Congenital heart disease  
1.4.5 Schistosomiasis 
1’. Pulmonary veno-occlusive disease and/or pulmonary capillary haemangiomatosis 
1”. Persistent pulmonary hypertension of the newborn 
2. Pulmonary hypertension due to left heart disease 
2.1 Left ventricular systolic dysfunction 
2.2 Left ventricular diastolic dysfunction 
2.3 Valvular disease 
2.4 Congenital/acquired left heart inflow/outflow tract obstruction and congenital cardiomyopathies 
2.5 Other 
 3. Pulmonary hypertension due to lung diseases and/or hypoxia 
3.1 Chronic obstructive pulmonary disease 
3.2 Interstitial lung disease 
3.3 Other pulmonary diseases with mixed restrictive and obstructive patterns 
3.4 Sleep-disordered breathing 
3.5 Alveolar hypoventilation disorders 
3.6 Chronic exposure to high altitude 
3.7 Developmental lung diseases 
4. Chronic thromboembolic pulmonary hypertension and other pulmonary artery obstructions 
4.1 Chronic thromboembolic pulmonary hypertension 
4.2 Other pulmonary artery obstructions 
5. Pulmonary hypertension with unclear and/or multifactorial mechanisms 
5.1 Haematological disorders: chronic haemolytic anaemia, myeloproliferative disorders and   
splenectomy 
5.2 Systemic disorders: sarcoidosis, pulmonary histiocytosis and lymphangioleiomyomatosis  
5.3 Metabolic disorders: glycogen storage disease, Gaucher disease and thyroid disorders 
5.4 Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure, and segmental PH 
 
BMPR2: bone morphogenic protein receptor type II; ALK1: activin receptor-like kinase 1; ENG: endoglin; 
CAV1: caveolin-1; KCNK3: potassium channel, two pore domain subfamily K, member 3.  (Updated from 
Simonneau et al. 2013) [4]. 
1.3 The epidemiology of pulmonary arterial hypertension 
Right heart catheterization is required for a reliable diagnosis of PH. This invasive 
examination procedure for epidemiology studies is not ethical or feasible which makes 
the incidence and prevalence of PH more difficult to study than that of systemic 
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hypertension. Large-scale, population-based epidemiology investigations must be based 
on echocardiography, although this is not the gold standard for diagnosing PH. According 
to the investigations and reports from registries, all age groups are affected by this 
condition, and it has rapidly growing importance in elderly people in countries with aging 
populations [6]. Present estimates suggest a PH prevalence of approximately 1% of the 
global population, which increases to 10% in individuals over 65 years old. This disease 
was estimated to affect 50 million to 70 million people worldwide in 2015 [6]. Thus, PH 
is a substantial global health issue [6]. 
Most of the registries for PAH are in developed countries [6]. The incidence of PAH 
in European countries ranges from 1.1 to 7.6 per million adults per year, and the 
prevalence of PAH is from 6.6 to 26.0 per million adults [6, 8-14]. The rough estimate for 
the global incidence of PAH is about five per million adults per year and the prevalence 
is approximately 15 per million adults. These numbers are generally underestimated 
because they do not include PAH associated with congenital heart disease, 
schistosomiasis, or HIV infection, which are prevalent in some countries of the world [6]. 
In addition, PAH affects young, female individuals [15]. Although female sex is a risk 
factor for this disease, females have better survival rates than males [15].         
1.4 The pathology of pulmonary arterial hypertension  
Pulmonary arterial hypertension has a multifactorial and complicated pathobiology [7]. 
The molecular mechanisms of PAH are still not clear, though the understanding has 
expanded significantly in recent years. Although the classification of PAH includes many 
different sub-categories, there is a common pathway which results from a combination 
of environmental factors and genetic predispositions. The different sub-categories of 
PAH are characterized by excessive pulmonary vasoconstriction and abnormal vascular 
remodeling processes that usually affect all vessel layers (Figure 1) [16, 17]. This 
vascular remodeling and its consequent pulmonary vascular obstruction lead to a 
progressive increase in pulmonary vascular resistance. This resistance increases right 
ventricular afterload, resulting in right ventricular hypertrophy and ultimately right 
ventricular failure and death. 
The abnormalities of the pulmonary vasculature include (1) abnormal muscularization 
of distal precapillary arteries, (2) medial hypertrophy and thickness of large pulmonary 
muscular arteries, (3) loss of precapillary arteries, (4) neointimal formation, and (5) 
formation of angio-proliferative plexiform lesions in these vessels [16]. 
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Figure 1. The pathobiology of pulmonary arterial hypertension.    
Scheme is illustrating the different vascular abnormalities associated with PAH compared to 
normal pulmonary circulation and depicts the abnormalities throughout the pulmonary circulation 
(Rabinovitch, 2012) [16]. 
1.5 The histology of pulmonary arterial hypertension 
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The pathological changes associated with PAH predominantly occur in the small distal 
pulmonary arteries (<500 μm), and do not affect pulmonary veins [7]. The histological 
features of PAH include the infiltration of inflammatory or progenitor cells, in situ 
thrombosis, the occlusion of small arteries, intimal hyperplasia, medial hypertrophy, 
adventitial proliferation or fibrosis, and angio-proliferative plexiform lesions (Figure 2) 
[18].  
   
Figure 2. Histology of PAH. 
Plexiform lesions are shown at the top. Evidence of cell proliferation is shown on the upper left; 
proliferating cell nuclear antigen (PCNA) is in red, smooth muscle (SM) actin is in green, and 
DAPI (4',6-diamidino-2-phenylindole) nucleus staining is in blue. Medial hypertrophy, intimal 
fibrosis, and adventitial proliferation are displayed at the bottom (Archer, 2010) [18]. 
1.6 Molecular mechanisms of pulmonary arterial hypertension 
 The imbalance of vasoactive mediators in the pathogenesis of pulmonary 
arterial hypertension  
The regulation of vascular tone is maintained by the balance between vasodilators 
such as nitric oxide (NO) and prostacyclin, and vasoconstrictors such as thromboxane 
A2 and endothelin-1 (ET-1) [19]. Endothelial dysfunction due to inflammation or shear 
stress is a primary cause of persistent vasoconstriction as it disrupts this balance. 
Excessive vasoconstriction is the result of endothelial dysfunction leading to the 
chronically impaired production of vasodilators and antiproliferative agents such as NO 
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and prostacyclin, along with overexpression of vasoconstrictors and proliferative 
substances such as thromboxane A2 and ET-1.   
 Nitric oxide 
Nitric oxide is synthesized in the endothelium by the endothelial NO synthase (eNOS), 
which catalyzes the oxidation of l-arginine to produce l-citrulline in the presence of 
oxygen, nicotinamide adenine dinucleotide phosphate (NADPH), and essential cofactors 
such as tetrahydrobiopterin (BH4). Once formed, NO diffuses from the endothelium to 
the vascular smooth muscle cell (SMC) and activates the sGC/cGMP pathway [20]. The 
activation of sGC converts guanosine 5’-triphosphate (GTP) to cyclic guanosine 3’,5’-
monophosphate (cGMP), which then activates downstream cGMP-dependent protein 
kinase G (PKG) and reduces intracellular calcium to induce vasodilation [20].  
The critical role of NO in the development of PAH is supported by the evidence of 
reduced eNOS expression in the pulmonary vasculature in PAH patients [21]. 
Furthermore, eNOS-null mice are more susceptible to chronic hypoxia that triggers PH 
than wild-type mice, suggesting that NO acts as a vasodilator and inhibits SMC 
proliferation, platelet aggregation, and thrombosis in the blood vessel lumen [22].  
 Prostacyclin 
Prostacyclin is a prostaglandin member of the eicosanoid family of lipid molecules. 
Prostacyclin is an effective vasodilator that can also attenuate vascular SMC 
proliferation, inhibit platelet aggregation, and exert anti-inflammatory and antithrombotic 
effects. Prostacyclin binds to its specific I-prostanoid receptor in the underlying SMCs to 
promote relaxation and subsequent vasodilation by activating adenylyl cyclase and 
increasing intracellular cAMP levels, which then activates protein kinase A (PKA) [23]. 
The level of prostacyclin decreases in patients with PAH [24], and the expression of 
prostacyclin receptors and synthases are reduced in these patients [25, 26]. Moreover, 
mice with prostacyclin receptor deficiency develop severe PAH and vascular remodeling 
after chronic hypoxia exposure [25]. This evidence indicates that prostacyclin plays an 
important role in the development of PAH.  
 Endothelin-1   
Endothelin-1 is one of the most potent vasoconstrictors in biology [27].  There are two 
different G-protein–coupled receptors: endothelin receptor type A (ETA) and endothelin 
receptor type B (ETB) for ET-1 binding [27]. Endothelin receptor type A receptors are 
predominantly expressed on vascular smooth muscle cells, and they mediate 
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vasoconstriction, proliferation, hypertrophy, cell migration, and fibrosis. Endothelin 
receptor type B receptors are located on ECs and SMCs. Although their activation on 
SMCs results in vasoconstriction, ETB activation on endothelial cells produces 
vasodilation and anti-proliferation by increasing the production of NO and prostacyclin 
[28].  
The level of ET-1 is elevated in patients with PAH and animals of the PAH model. Big 
ET-1 (precursor of ET-1) level in the plasma also increases in PAH patients [29-31]. In 
addition, the expression of constrictive ETA and ETB both increase on SMCs, and 
decreased expression of vasodilatory ETB has been found in ECs as PAH progresses 
[28]. An increasing number of translational therapies targeting the NO–sGC–cGMP 
pathway, prostacyclin pathway, and endothelin-1 pathway have been effective in the 
treatment of PAH in the clinic (Figure 3) [20], which confirms the importance of these 
three pathways in the development of PAH. 
 The role of growth factors in pulmonary arterial hypertension 
Growth factors such as platelet-derived growth factor (PDGF), fibroblast growth factor 
(FGF), transforming growth factor β (TGFβ), vascular endothelial growth factor (VEGF), 
and hepatocyte growth factor (HGF) are involved in the remodeling process in PAH [7]. 
Growth factors are potent mitogens and chemoattractants for vascular cells, such as 
SMCs, fibroblasts, and ECs. Activation of cell surface tyrosine kinase receptors (TKR) 
initiates major intracellular signaling cascades. These signaling cascades control many 
cellular functions and processes, including cellular proliferation, migration, differentiation, 
resistance to apoptosis, and extracellular matrix deposition [17].   
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Figure 3. Classic vasodilator and vasoconstrictor systems and their translational 
therapies for PAH. 
Nitric oxide activates the vasodilation and antiproliferation of SMC via a cGMP-dependent mechanism. 
Inhalation of NO, administration of nitrite or nitrate, sGC stimulator (riociguat), phosphodiesterase 5 (PDE5) 
inhibitors (sildenafil and tadalafil), and BH4 analog (6R-BH4) have been effective in the treatment of PAH. 
Prostacyclin activates vasodilation and inhibits proliferation of smooth muscle cells via a cAMP-dependent 
mechanism. Prostacyclin and its derivatives (epoprostenol, treprostinil, iloprost, and beraprost) and I-
prostanoid (IP) receptor agonists (selexipag) provide therapeutic benefit in PAH, and ET-1 stimulates 
vasoconstriction and proliferation via activation of ETA and ETB receptors on SMC. In addition, ETA blocker 
(ambrisentan) and dual ET-1 blockers (bosentan and macitentan) are useful in the treatment of PAH; AC 
indicates adenylyl cyclase; BH2, dihydrobiopterin; COX, cyclooxygenase; ECEs, endothelin-converting 
enzymes; eNOS, endothelial NO synthase; FDA, Food and Drug Administration (Lai, 2014) [20]. 
 Platelet-derived growth factor 
Platelet-derived growth factor (PDGF) acts as a potent mitogen and chemoattractant 
for pulmonary artery smooth muscle cells (PASMCs). The expression of PDGF and its 
receptor is elevated in the lungs of patients with PAH, and PDGF receptor expression is 
increased in experimental PH models [32-35]. Imatinib, the first tyrosine kinase inhibitor 
(TKI) for the treatment of chronic myeloid leukemia (CML), reversed advanced 
pulmonary vascular disease in two animal models of PH by inhibiting PDGF signaling 
[36]. In a randomized, multicenter, placebo controlled phase III trial, imatinib 
demonstrated efficacy, improved exercise capacity and hemodynamics in patients with 
advanced PAH (IMPRES trial)  [37].      
 Fibroblast growth factor  
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Fibroblast growth factor 2 (FGF2), also known as bFGF or FGF-β, is a member of the 
fibroblast growth factor family. Fibroblast growth factor 2 levels in plasma and urine are 
significantly elevated in patients with PAH [38]. Furthermore, hypoxia and shear-stress-
induced FGF2 upregulation is observed in rat and ovine pulmonary arterial SMC [39, 40], 
and upregulation of FGF-2 occurs in lambs with PH [41], but not in hypoxic mice [42]. 
Fibroblast growth factor 2 small interfering RNA treatment prevents lung FGF2 
production and almost reverses monocrotaline-induced PH in rats [43]. In addition, the 
pharmacological inhibition of FGF receptor 1 reverses established PH in the same model 
[43]. 
 Hepatocyte growth factor 
Hepatocyte growth factor is secreted by mesenchymal cells and it acts as a multi-
functional cytokine, primarily on cells of epithelial origin; it signals these cells through 
tyrosine phosphorylation of its receptor, c-Met. Hepatocyte growth factor expression 
downregulates under hypoxia in vascular cells and organ culture systems [44], and HGF 
production is decreased in monocrotaline-induced PH in rats [45]. Moreover, HGF gene 
transfer inhibits vascular medial hyperplasia and matrix accumulation to attenuate the 
development of monocrotaline-induced PH in rats [45, 46].  This growth factor might have 
a protective role in pulmonary vascular remodeling, but more preclinical and clinical 
studies are required to confirm this.  
 Vascular endothelial growth factor 
Vascular endothelial growth factor is a sub-family of the PDGF family which has five 
members: placental growth factor and VEGF A, B, C, and D. The expression of VEGF 
and VEGF receptor 2 (VEGFR-2) is upregulated in the plexiform lesions of patients with 
PAH [47, 48], indicating a role for VEGF in the pathogenesis of PAH. However, data from 
animal models have been inconsistent. Vascular endothelial growth factor is down-
regulated in rats with monocrotaline-induced PH, but increased in rats with chronic 
hypoxic PH [49, 50]. The VEGFR-2 antagonist Sugen5416 is combined with chronic 
hypoxia in rats, and induces severe PH with angioproliferative lesions (plexiform lesions) 
[51]. Thus, the inhibition of VEGF plays a role in the development of PH. However, the 
inhibition of VEGF signaling (and others) by the multikinase inhibitor sorafenib in rats 
attenuates experimental PH (i.e. monocrotaline-induced or VEGFR inhibition combined 
with hypoxia) [52, 53]. The controversies regarding the role of VEGF in the pathogenesis 
of PH continue, as results from experiments that used VEGF treatment for rats with 
established PH show that it aggravated the disease [54]. However, gene-transfer-
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mediated VEGF overexpression attenuates the development of experimental PH in rats 
(monocrotaline-induced, pulmonary fibrosis, and hypoxic models) [55-57].  
 Epidermal growth factor  
Transforming growth factor alpha (TGF-α), a member of the EGF family, is a mitogenic 
polypeptide. Pulmonary overexpression of TGF-α results in vascular remodeling and the 
development of PH in mice [58]. The inhibition of the EGF receptors attenuates 
monocrotaline-induced PH in rats [59, 60], but it does not improve chronic hypoxia-
induced PH in mice [59].   
 Transforming growth factor β  
The TGF-β superfamily is involved in regulating homeostasis and multiple cellular 
functions, including proliferation, differentiation, apoptosis and endothelial mesenchymal 
transition (endo-MT) [61]. The TGF-β superfamily is comprised of a large series of 
cytokine growth factors. Transforming growth factor β members are cataloged into 
several subfamilies, including the prototypic TGF-β ligands, receptors, accessory 
molecules, activins, and the bone morphogenetic proteins (BMP) which are the largest 
of these groups [62]. Among them, BMP receptor 2 (BMPR2), activin receptor-like kinase 
1 (ALK1), and endoglin (ENG) are recognized as causal factors in hereditary and 
associated forms of PAH [63]. Bone morphogenetic protein receptor 2 encodes a type 2 
receptor for bone morphogenetic proteins involved in the control of vascular cell 
proliferation. Mutations in these receptors have been identified that account for 
approximately 75% of patients with a known family history of PAH, and up to 25% of 
apparently sporadic cases [64]. Bone morphogenetic protein receptor 2 is the major 
predisposing gene and BMPR2 defects in this gene are the major genetic determinant 
underlying PAH. Other genes related to TGF-β superfamily receptor signaling have been 
identified as rare causes of PAH.  For example, ALK1 and ENG are present when PAH 
is associated with hereditary hemorrhagic telangiectasia [65, 66]. 
 The role of inflammation in pulmonary arterial hypertension 
Inflammation plays a prominent role in the initiation and progression of human PAH 
and in experimental models of PH [7, 67]. Monocytes, macrophages, T lymphocytes and 
dendritic cells are found in plexiform lesions and other vascular lesions of PAH-affected 
human lungs [68]. Furthermore, inflammation contributes to the growth of pulmonary 
plexiform lesions which are characteristic features of PAH [69]. The inflammatory cells 
and cytokines and chemokines which induced by these cells all regulate the growth, 
migration, and differentiation of all cell types, leading to vascular remodeling [67].  
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The circulating levels of monocyte chemoattractant protein 1, tumor necrosis factor 
(TNF), interleukin-1β (IL-1β), and interleukin-6 (IL-6) were increased in patients with 
idiopathic pulmonary arterial hypertension (IPAH) [70, 71]. Animal models also support 
the role of inflammatory cytokines in the initiation, development, and progression of PAH. 
Monocrotaline-treated (MCT) rats showed increased IL-1 expression in their lungs, and 
repeated injections of an IL-1 receptor antagonist reduced PH and right heart 
hypertrophy in this MCT model [72]. Increased IL-6 expression was also found in the 
MCT model, and rats injected with IL-6 developed PH [73, 74]. Furthermore, 
overexpression of IL-6-induced PH in mice [75], and IL-6-deficient mice were protected 
from hypoxia-driven lung inflammation and pulmonary vascular remodeling in this animal 
model [76]. Cytokines can be also used as biomarkers to diagnose PAH in patients. 
 Collagen deposition and fibrosis in pulmonary arterial hypertension 
Excessive vascular collagen accumulation in the large pulmonary arteries of rats with 
hypoxic PH plays a role in decreased pulmonary vascular compliance [77], and the 
expression of collagen 1 in hypoxic mice prevents the mechanical properties of the 
extralobar pulmonary arteries from returning to normal after removal from hypoxic 
conditions [78]. In addition to the pathogenesis mentioned above, thrombosis, proteases, 
elastases, peroxisome proliferator-activated receptors (PPARs), and mitochondrial 
dysfunction are all involved in the initiation and development of PAH [7]. 
1.7 Treatment 
Although there are several treatment options available, there is no cure for PAH. The 
treatment process of PAH patients cannot be considered solely as the prescription of 
drugs, as it is characterized by a complex strategy that includes the initial evaluation of 
severity and the subsequent response to treatment [5]. 
Treatment for PAH includes conventional therapy and specific drug therapy by 
vasodilators. Conventional therapy for PAH can include oral anticoagulation, diuretics, 
supplemental oxygen, and digoxin, and other cardiovascular drugs. Lung or heart-lung 
transplants are treatment options that are reserved for patients who are not improving 
with medical therapies [5]. 
Three separate signaling pathways involved in vascular dilation can be addressed 
with specific approved drugs for the specific drug therapy [79]. Prostacyclin 
(epoprostenol), prostacyclin analogs, and prostacyclin receptor agonists are applied to 
target the prostacyclin pathway. In addition, phosphodiesterase type 5 inhibitors and 
guanylate cyclase stimulators address the NO pathway and endothelium receptor 
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antagonists are applied to inhibit the endothelin pathway. The clinical experiences and 
meta-analysis show that combinations of therapies with existing drugs under different 
mechanisms of action maximize therapeutic benefits and minimize side effects [5]. 
To further improve symptoms and prognosis, in addition to these three well-known 
pathways, therapeutic strategies targeted at diverse pathobiological changes are being 
explored. The following compounds are under investigation for future use: TKIs, rho 
kinase inhibitors, VEGF receptor inhibitors, angiopoietin-1 inhibitors, and elastase 
inhibitors [5]. 
1.8 Animal models of pulmonary hypertension 
To understand the pathophysiological mechanisms underlying the pathogenesis of 
PAH and to find an effective treatment for PAH, animal models are used to simulate the 
disease. There are several well-accepted animal models established that mimic the 
human situation, including MCT-induced PH, hypoxia-induced PH, and Sugen5416 plus 
chronic hypoxia exposure induced PH [80-83].  
MCT-induced PH is the oldest model and it is still frequently investigated [83, 84]. 
However, the neointima lesions observed in patients with PAH are not formed in MCT-
induced PH rats. Moreover, many agents that are not efficacious for PAH patients have 
been reported to prevent or cure vascular remodeling in this model [82]. Chronic hypoxia 
is the most commonly used physiological stimulus for PH development in animal models. 
This experimental model of PH represents group 3 of the PH classification. The main 
issue with this animal model is that remodeling is reversed after returning to normoxic 
conditions.  
A rat model that mimics the pulmonary vascular changes as seen in human PAH, was 
recently developed. It is a combination of a single subcutaneous injection of the VEGF 
receptor inhibitor Sugen5416 together with exposure to chronic hypoxia (SuHx) for 3–5 
weeks followed by re-exposure to normoxia [85]. The SuHx rat develop endothelial cell 
proliferation, an occlusion of small precapillary arterioles and vascular remodeling that 
does not reverse after being re-exposed to normoxia [86]. This model is relevant to 
human PAH because pulmonary hypertension is severe, progressive and refractory to 
treatment as it is in most PAH patients [81, 86].  
1.9 Antifibrotic drug: Pirfenidone 
Pirfenidone is an orally available pyridone analog [5-methyl-1-phenyl-2-(1H)-
pyridone]; it is multifunctional with antifibrotic, anti-inflammatory, and antioxidant 
activities [87]. This drug was initially developed as an anti-inflammatory agent in 1967, 
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but the focus was then shifted to developing pirfenidone as an antifibrotic agent since it 
was found to have antifibrotic activity in a hamster model of bleomycin-induced lung 
fibrosis [87-89]. Pirfenidone also showed antifibrotic properties in several animal models 
of heart, liver, and renal fibrosis [89, 90].  
Pirfenidone was first approved for idiopathic pulmonary fibrosis (IPF) treatment in 
Japan in 2008. However, it was not approved by the US Food and Drug Administration 
(FDA) in the United States of America (USA) due to conflicting results of phase III trials 
assessing the efficacy of pirfenidone from the SP3 trial in Japan and the multinational 
CAPACITY trials [91, 92]. Additional clinical evidence to support the use of pirfenidone 
in the USA was requested by the FDA. To assess and confirm the efficacy and safety of 
pirfenidone, the ASCEND study was performed in IPF patients. In this clinical trial, 
pirfenidone demonstrated remarkable efficacy in IPF treatment, including a significant 
reduction in the primary endpoint, a decline in forced vital capacity (FVC) over one year, 
less decline in the six-minute walk test distance, and improved progression-free survival. 
No side effects were reported related to respiratory symptoms or mortality [93-95]. The 
FDA granted pirfenidone (Esbriet) fast track status, priority review, orphan drug 
designation, and breakthrough therapy designation [96], and pirfenidone was approved 
on 15 Oct 2014 by the FDA [96]. In addition to its clinical indication for IPF, a randomized 
and placebo-controlled clinical trial showed that pirfenidone also has potential benefits 
for diabetic nephropathy [97].  
The key target molecule and precise mechanism of action for pirfenidone are not 
clear, and further studies are needed to explore its precise mechanism of action. 
Pirfenidone appears to exert inhibitory effects on multiple pathways that lead to the 
development of IPF as shown in Figure 4 [87]. The antifibrotic efficacy of pirfenidone is 
likely due to the inhibition of TGF-β, which is an important pro-fibrotic cytokine and 
biomarker of lung fibrosis that is extensively involved in the development of lung fibrosis 
[98]. The mechanism of action for pirfenidone also includes suppression of inflammation 
by regulating the expression of pro-fibrotic factors and proinflammatory cytokines. 
Pirfenidone demonstrates attenuation of the expression of IL-1β, IL-6, and TNF-α to 
decrease the fibrotic response [87, 99]. A reduction in oxidative stress is another 
mechanism of pirfenidone for treating lung fibrosis. Misra’s research found that 
pirfenidone inhibited NADPH-dependent microsomal lipid peroxidation and scavenged 
hydroxyl radicals [100].   
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Figure 4. Potential mechanisms for the suppression of fibrogenesis by pirfenidone. 
Notes: Pirfenidone may inhibit the production of pro-fibrotic cytokines, inflammatory cytokines, 
collagen-specific chaperone HSP-47, and reactive oxygen species, and stimulate the production 
of IFN-γ and IL-10. It has, however, limited suppressive activity for immunity, which is strongly 
suppressed by corticosteroids. ECM, extracellular matrix; FGF, fibroblast growth factor; HSP, 
heat shock protein; IFN, interferon; IL, interleukin; MCP, monocyte chemoattractant protein; NOX, 
NADPH oxidase isoform; PDGF, platelet-derived growth factor; ROS, reactive oxygen species; 
TGF, transforming growth factor; TNF, tumor necrosis factor (Takeda, 2014) [87]. 
1.10 Antifibrotic drug: Nintedanib 
Nintedanib is a tyrosine kinase inhibitor (TKI) for the treatment of IPF and non-small-
cell lung cancer from Boehringer Ingelheim, Germany. Nintedanib (formerly known by its 
development code BIBF 1120), is a small molecule that was originally designed as an 
ATP-competitive inhibitor of fibroblast growth factor receptor 1 (FGFR 1) and vascular 
endothelial growth factor receptor 2 (VEGFR 2) [101, 102]. Both of these tyrosine kinases 
receptors are pro-angiogenic, and BIBF1120 was selected as an antiangiogenic drug 
and developed for cancer therapy. Nintedanib is approved in Europe for non-small-cell 
lung cancer patients with advanced adenocarcinoma after first-line chemotherapy [103].  
Studies also show that nintedanib is also a potent inhibitor of platelet-derived growth 
factor receptor (PDGFR)-α and β, and a new indication for nintedanib was appointed for 
its development as a potential treatment for IPF [103, 104]. Two phase III clinical trials, 
INPULSIS-1 and INPULSIS-2, showed that nintedanib slowed disease progression in 
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patients with IPF by reducing the annual rate of decline in forced vital capacity (FVC) 
[105].  
Nintedanib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs) 
and non-receptor tyrosine kinases (nRTKs) [106]. Nintedanib inhibits the following RTKs: 
PDGFR α and β, FGFR 1-3, VEGFR 1-3, and Fms-like tyrosine kinase-3 (FLT3). Among 
them, FGFR, PDGFR, and VEGFR have been implicated in IPF pathogenesis [107]. 
Nintedanib binds competitively to the ATP binding pocket of these receptors and blocks 
intracellular signaling for the proliferation, migration, and transformation of fibroblasts, 
representing the essential mechanisms of IPF pathology. The following nRTKs were 
inhibited by nintedanib: Lck, Lyn, and Src kinases [106]. 
             
 
Figure 5. The pharmacology of nintedanib and the downstream signaling pathways. 
FAK: focal adhesion kinase; FGF: fibroblast growth factor; FRS2: FGFR substrate 2; Grb2: growth 
factor receptor-bound protein 2; MEK1/2: mitogen-activated protein kinase 1/2; PDGF: platelet-
derived growth factor; PI3K: phosphatidylinositol-4,5-bisphosphate 3-kinase; PIP2/3: 
phosphatidylinositol-2/3-phosphate; PKC: protein kinase C; PLC-γ: phospholipase C-γ; SOS: son 
of sevenless, a guanine nucleotide exchange factor that acts on the Ras GTPases (Wollin, 2015) 
[106]. 
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2 AIMS OF THE STUDY 
Pulmonary arterial hypertension is caused by an obliterative pulmonary vasculopathy 
that predominantly affects small pulmonary arteries. PAH is characterized by excessive 
vasoconstriction due to the dysregulation of vascular tone and thickening of vessel walls 
caused by the abnormal proliferation of vascular SMCs. Current pharmacotherapies 
which are approved for treatment of PAH focus on vasodilation, including substances 
like calcium channel blockers, prostacyclin, prostacyclin analogs, prostacyclin receptor 
agonists, phosphodiesterase type 5 inhibitors, soluble guanylate cyclase stimulators and 
endothelium receptor antagonists [79]. Although these therapeutic approaches relieve 
the pulmonary vasoconstrictive component of the disease and provide symptomatic relief 
with some amelioration in the prognosis, there is no strong evidence to support that these 
vasodilators have a direct antiproliferative effect on pulmonary vascular cells, and the 
underlying pathological pulmonary vascular and right ventricular remodeling is still 
progressing.  
Future medical intervention strategies must therefore go beyond vasodilation, to 
target vascular remodeling in the pulmonary vasculature. There are several drug 
candidates that focus on vascular remodeling currently under investigation. These new 
therapeutic agents must be continuously explored because of the insufficient efficacy 
and poor tolerability of these compounds. 
It was found found that PDGF-induced collagen synthesis is involved in pulmonary 
vascular remodeling [108]. The immunohistochemistry staining in figure 6 shows that 
collagen expression is higher in the smooth muscle cells from lung tissue of the PAH 
patient than that from lung tissue of the healthy donor. In experimental PAH, collagen 
deposition in the smooth muscle cells is increased compared to control (figure 6, next 
page).   
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Figure 6. Collagen deposition in the SMC from IPAH and experimental PAH. (Unpublished 
data in our lab, staining by Ewa Bieniek) 
 
Based on the antifibrotic effect of pirfenidone and nintedanib in experimental 
pulmonary fibrosis and IPF patients, the hypothesis of this study was that 
pirfenidone/nintedanib may inhibit collagen synthesis and the cell proliferation of 
PASMCs induced by growth factors in PH. Thus, the effects of pirfenidone and 
nintedanib were investigated on hemodynamics and pulmonary vascular remodeling in 
a rat model of experimental PAH induced by single injection of Sugen5416 and hypoxic 
exposure (SuHx). In addition, the downstream of effects on the cellular and molecular 
level were analyzed to explore the mechanism of action of pirfenidone and nintedanib.  
The following experiments were conducted: 
1. The effect of pirfenidone on hPASMCs proliferation induced by PDGF-BB or multi-
growth factors 
2. The effect of pirfenidone on hPASMCs migration induced by PDGF-BB 
3. The effect of pirfenidone on collagen expression and secretion 
4. The effect of pirfenidone on mRNA expression of proinflammatory cytokines  
5. An evaluation of the in vivo effects of pirfenidone in PAH rats, including indexes of 
right ventricular systolic pressure, right ventricle function and hypertrophy, vascular 
remodeling, collagen expression and inflammation  
6. An investigation of the mechanism of action of pirfenidone 
7. The effect of nintedanib on hPASMCs proliferation induced by PDGF-BB or multi-
growth factors 
8. The effect of nintedanib on hPASMCs migration induced by PDGF-BB 
9. The effect of nintedanib on collagen expression and secretion 
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10. The effect of nintedanib and proinflammatory cytokines on mRNA expression 
11. An evaluation of the in vivo effects of nintedanib on SuHx rats 
12. An investigation of the mechanism of action of nintedanib 
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3 MATERIALS AND METHODS   
3.1 Materials 
 Chemicals, reagents, kits 
Product Company 
2-propanol Sigma- Aldrich, Germany 
Acetic acid Sigma- Aldrich, Germany 
Acrylamide Roth, Germany 
Ammonium persulfate (APS) Sigma- Aldrich, Germany 
Bovine serum albumin (2 mg/ml) Bio-Rad, USA 
Bovine serum albumin (20 mg/ml) Sigma-Aldrich, USA 
Bovine serum albumin powder Serva, Germany 
Bromophenol blue  Merck, Germany 
Cell Proliferation ELISA, BrdU (colorimetric) Roche, USA 
DAB substrate kit Vector, Germany 
DC™Protein Assay Bio-Rad, USA 
DEPC water Roth, Germany 
Dimethyl sulfoxide (DMSO)  Sigma-Aldrich, USA 
Disodium phosphate (Na2HPO4) Roth, Germany 
DNeasy Blood & Tissue Kit Qiagen, Germany 
Enhanced chemiluminescence (ECL) kit Amersham, USA 
Ethanol 70%  SAV LP, Germany  
Ethanol 96%  Otto Fischhar, Germany 
Ethanol 99.9% Berkel AHK, Germany 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich, USA 
Glycerol Sigma-Aldrich, USA 
Glycine   Roth, Germany 
Heparin Ratiopharm, Germany 
Hydrogen peroxide 30% Vector, Germany 
ImPRESEE Kit anti-rabbit Ig Vector, Germany 
iScript cDNA synthesis kit Bio-Rad, USA 
Isoflurane Baxter, UK  
iTaq SYBR Green Supermix Bio-Rad, USA 
Ketamine  Bela Pharm, Germany 
Monopotassium phosphate (KH2PO4) Roth, Germany 
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Nintedanib Boehringer Ingelheim, Germany 
Non-fat milk powder Roth, Germany 
Normal horse serum Vector, Germany 
Normal rabbit serum Vector, Germany 
Paraformaldehyde (PFA) 3.7% Sigma-Aldrich, USA 
Paraplast® Plus paraffin embedding medium Sigma-Aldrich, USA 
Pertex® mounting medium Medite, Germany 
PDGF-BB PeproTech, USA 
Pirfenidone Roche, Swiss 
Potassium chloride (KCl)    Sigma-Aldrich, USA 
Positively charged glass slides Langenbrinck, Germany 
Precision Plus Protein Standards Bio-Rad, USA 
RIPA buffer Santa Cruz, USA 
RNAse-Away Thermo Fisher, USA 
RNeasy Plus Mini Kit Qiagen, Germany 
Saline (NaCl 0.9%) B. Braun, Germany 
SDS Solution, 20% w/v AppliChem, Germany 
SIRCOL collagen assay Biocolor Ltd., UK 
Sodium chloride (NaCl)  Sigma-Aldrich, USA 
Sodium Orthovanadat (Na3VO4) Sigma-Aldrich, USA 
Sugen 5416  Tocris, UK 
Tetramethylethylenediamine (TEMED)  Sigma-Aldrich, USA 
Tissue-Tek® O.C. T™ Compound Sakura, Japan 
Tris Base Roth, Germany 
Tris-HCl Roth, Germany 
Triton-X100 Sigma-Aldrich, USA 
Tween®20 Sigma-Aldrich, USA 
UltraPure water Cayman Europe, Estonia  
Xylol (isomere) >98% pure, for histology   Roche, Germany  
β-Mercaptoethanol Sigma-Aldrich, USA 
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 Cell culture medium 
Name                                                                                    Company  
DPBS                                                                                     PAN, Germany  
Fetal bovine serum Roth, Germany 
Smooth Muscle Basal Medium (SmBM )                                Lonza, Germany 
Smooth Muscle Growth Medium-2 (SmGM-2) 
SingleQuot Kit Suppl. & Growth Factors           
Lonza, Germany 
Trypsin/EDTA  PAN, Germany 
 Antibodies 
 Primary antibodies 
Table 2 Primary antibodies 
Antibody  
(catalog number) 
Host Company 
Akt 
(9272) 
rabbit polyclonal antibody Cell Signaling, USA 
p-Akt 
(9271) 
rabbit polyclonal antibody Cell Signaling, USA 
CD 68 
(MCA341R) 
mouse monoclonal antibody Bio-Rad, USA 
Collagen 1, 
(600-401-103-0.1 ) 
rabbit polyclonal antibody Rockland, USA 
Pan-actin 
(4968) 
rabbit polyclonal antibody Cell Signaling, USA 
PCNA(FL-261) 
(sc-7907) 
rabbit polyclonal antibody Santa Cruz, USA 
PDGFR-β (958) 
(sc-432) 
rabbit polyclonal antibody Santa Cruz, USA 
p-PDGFR-β (Tyr 1021)-R 
(sc-12909-R) 
rabbit polyclonal antibody Santa Cruz, USA 
PI3 Kinase p85 (19H8),   
(4257) 
rabbit polyclonal antibody Cell Signaling, USA 
p-PI3 Kinase p85/p55   
(4228) 
rabbit polyclonal antibody Cell Signaling, USA 
 Secondary antibody 
Horseradish peroxidase (HRP)–conjugated secondary antibody: 
Sheep anti-rabbit IgG (1:50000) GE Healthcare, PA, USA  
Donkey anti-mouse IgG (1:50000) GE Healthcare, PA, USA 
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 Primers  
Table 3  Primers for quantitative RT-PCR 
Gene  Primer Sequence 
Human  IL-1β 
Forward 5’ CAGACCTTCCAGGAGAATGAC 3’ 
Reverse 5’ AGGTGGAGAGCTTTCAGTTCA 3’ 
Human  IL-6 
Forward 5’ ACAGACAGCCACTCACCTCTT  3’ 
Reverse 5’ TGGAAGGTTCAGGTTGTTTTC 3’ 
Human  HPRT 
Forward 5’ TGACACTGGCAAAACAATGCA 3’ 
Reverse 5’ GGTCCTTTTCACCAGCAAGCT 3’ 
Rat  IL-1β 
Forward 5’ GGCTTCCTTGTGCAAGTGTC 3’ 
Reverse 5’ TGTCGAGATGCTGCTGTGAG 3’ 
Rat IL-6 
Forward 5’ AGAGACTTCCAGCCAGTTGC 3’ 
Reverse 5’ TGCCATTGCACAACTCTTTTCT 3’ 
Rat collagen 1a1 
Forward 5’ GCTCCCCAGCTGTCTTATGG 3’ 
Reverse 5’ CAATCCTCGAGCACCCTGAG 3’ 
Rat collagen 3a1 
Forward 5’ GCTGGCATCAAAGGACATCG 3’ 
Reverse 5’ GGGAGCCCTCAGATCCTCTT 3’ 
Rat  HPRT 
Forward 5’ ACAGGCCAGACTTTGTTGGAT 3’ 
Reverse 5’ GGCCACAGGACTAGAACGTC3’ 
 
 Equipments 
Equipment                                                                       Company 
Balance 1.0-3000g RP 3000    AugustSauter, Switzerland 
Balance PCB 200-2 Precision     Kern, Germany 
Balance XS205      MettlerToledo, Switzerland 
BioDoc Analyzer      Biometra, USA 
Cell culture incubator, Hera Cell                         Heraeus, Germany 
Centrifuge Roranta 460R     Hettich, Germany 
Cytospin™ 4 Cytocentrifuge    Thermo Scientific, USA     
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Electrophoresis chamber     Bio-Rad, USA 
Freezer (+4°C, -20 °C, -80 °C)     Bosch, Germany 
Hypoxia Chambers                                                          Bio Spherix, USA 
Hypoxic gas (10% O2) ventilation                                    Praxair, Germany             
Infinite® 200 microplate reader     Tecan, Switzerland 
Inolab PH meter       WTW, Germany 
Light microscope DM IL      Leica, Germany 
LightCycler® 480 Instrument    Roche, Germany 
Liquidator 96      Steinbrenner, Germany 
Live imaging microscope DMI6000 B    Leica, Germany 
Microtome RM2165     Leica, Germany 
Mounting bath HI1210      Leica, Germany  
Mounting heating plate HI1220     Leica, Germany  
Multifuge centrifuge     Heraeus, Germany  
Mx3000P qPCR System               Stratagene, USA 
Normoxic gas (21% O2) ventilation                                  Praxair, Germany 
Pipetboy and pipettes                Eppendorf, USA  
Precellys®24 homogenizer   BertinTech., France 
Rotator Staurt®SB3     Bibby Scientific, U.K. 
Shaker       Bruker, Belgium 
Thermocycler T3000     Biometra, USA 
Vevo® 2100 system                                                         VisualSonics, Canada 
Vortex machine      VWR, Germany  
Water bath for cell culture     HLC, Germany  
Water bath for tubes     Medingen, Germany 
Western blot unit      Bio-Rad, USA 
 Other materials 
Materials name                                                                Company 
6-well, 24-well, 96-well microplate               Corning, USA  
96er PCR-plate for LC480     Steinbrenner, Germany 
AGFA cronex 5 medical X-ray film              AGFA, Belgium 
Chromatography column     Bio-Rad, USA 
Cover glass 60 x 24 (0.13-0.18 mm)    Langenbrinck, Germany 
Falcon tubes      BD Biosciences, USA  
Film cassettes      Kodak, USA 
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Filter tips (10, 100, 1000µl)     Nerbe plus, Germany 
Gel blotting paper       Whatman, USA 
Glass pipettes, cell culture dishes, plates   Sarstedt, Germany 
Glass slides Super Frost® Plus    R.La ngenbrinck, Germany 
Micro-Insert 4 Well                                                            Ibidi, Germany  
Needles 26-20G (0.45-0.9mm)     Microlance™ 3 BD, Ireland  
Nitrocellulose membrane     Bio-Rad, USA 
     Precellys bead mill sample tube   Berlin Tech, France  
Radiographic films hypersensitive    Amersham, USA  
Radiographic films      Santa Cruz, USA 
Scalpels       Feather, Japan 
Shandon™ Single Cytoslides™    Thermo Scientific, USA 
Syringes 1, 2, 5, 10, 25 ml     B. Braun, Germany 
Tips (10, 100, 1000 µl)     Eppendorf, USA   
 Computer software 
Software       Company 
Fluorescence (LAS AF) Microscope Software  Leica, Germany  
i-Control       Tecan, Austria  
Leica Application Suite Advanced    Leica, Germany 
Leica QWin Imaging Software    Leica, Germany  
LightCycler® 480 Software    Roche, Germany 
Magellan v.6.3      Tecan, Austria MS®  
MxPro™ QPCR Software     Agilent Technologies, USA 
Prism® v6.05      GraphPad statistics, USA 
3.2 Methods 
 Human pulmonary artery smooth muscle cells culture 
Pulmonary artery smooth muscle cells from healthy donors were purchased from 
Lonza (Basel, Switzerland). They were cultured on cell-culture dishes in smooth-muscle 
growth medium (SmGM-2) from Lonza (Basel, Switzerland) and incubated in a humidified 
atmosphere of 95% air and 5% CO2 at 37°C.  
 Cryopreservation 
At 80% confluency, cells were washed with DPBS buffer and trypsinization was 
performed by adding pre-warmed trypsin. Growth medium was added to stop the trypsin 
activity, and the cells were then centrifuged at 1,000 rpm and 20°C for five minutes. The 
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pellet was then resuspended in a cooled freezing cryopreservation medium (SmGM-2: 
DMSO, 9:1), kept in a cell-freezing container for 24 hours at -80°C, and later transferred 
to liquid nitrogen and stored for future use.  
 Seeding and splitting 
The appropriate volume of medium was pre-incubated at 37°C and 5% CO2 for 30 
minutes. The cryopreserved cells were thawed and seeded to the plates containing a pre-
incubated medium, and they were incubated at 37°C and 5% CO2 until the cell 
confluency reached 80%. The cells were trypsinized and cell pellets were re-suspended 
in the fresh SmGM-2 growth medium, and the cell count and viability were determined 
using a hemocytometer and trypan blue. The cells were seeded at a seeding density of 
3,500 cells/cm2. 
 Cell proliferation assay 
Pulmonary artery smooth muscle cells were plated in a 96-well plate with 4000 cells 
per well. After serum starvation for 24h, the cells were stimulated with human 
recombinant PDGF-BB or multiple growth factors (MGF) in the presence or absence of 
pirfenidone/nintedanib for 24h.The proliferation of hPASMCs was assayed with a kit from 
Roche (Basel, Switzerland) that monitors the incorporation of 5-bromo-2deoxyuridine 
(BrdU) into newly synthesized DNA; BrdU was detected using anti-BrdU–peroxidase 
conjugate in accordance with the manufacturer’s instructions. After the reactions were 
stopped, absorbance at 450 nm was measured using a Tecan infinite multi-mode 
microplate reader, and the cell viability was checked using a WST-1 assay (Roche, 
Basel, Switzerland) and following the manufacturer's protocols. 
 Cell migration assays 
Cell migration was performed with wound-healing assays. Pulmonary artery smooth 
muscle cells were digested with 0.05% trypsin and dispersed into homogeneous cell 
suspensions; they were plated in low 35-mm μ-dishes with culture inserts (Ibidi, 
Martinsried, Germany).  Inserts were then removed with sterile forceps to create a wound 
field of approximately 500 μm. Cells were stimulated with 30 ng/ml of human recombinant 
PDGF-BB for migration in the presence or absence of pirfenidone or nintedanib for 24h. 
Migration was measured by photomicrography after cells were fluorescently labeled. The 
results are expressed as the number of migrated cells in this field. 
 Collagen assay 
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Pulmonary artery smooth muscle cells were plated in a 10-cm dish. After serum-
starvation for 24h, the cells were stimulated with 30 ng/ml of human recombinant PDGF-
BB in the presence or absence of pirfenidone or nintedanib for 72h. Collagen in the 
medium was measured using the Sircol soluble collagen assay (Biocolor, 
Newtownabbey, Northern Ireland) following the manufacturer’s protocol. After isolation 
and concentration, 100 μl of the sample was added to 1 ml of the colorimetric reagent 
(the SR dye in picric acid) and agitated for 30 min followed by centrifugation at 12,000 
rpm for 10 min. The SR dye was released from the pellet with the alkali reagent, and 
spectrophotometric readings were taken at 555 nm on a Tecan infinite multi-mode 
microplate reader.  
 Animals 
Adult male 10-12-week-old CD rats with body weights between 200g and 250g were 
obtained from Charles River Laboratories. Animal study protocols (GI20/10, number 
33/2013; GI20/10, number 47/2015) were approved by the University Animal Care 
Committee and the Federal Authorities for Animal Research of the Regierungspraesidium 
Giessen (Hessen, Germany). Rats were housed at room temperature (RT) with 12-hour 
light and dark cycles and free access to food and water. 
 Sugen5416 plus hypoxia induced PAH rat model 
Sugen5416 was dissolved in DMSO at a concentration of 25 mg/ml. Adult rats (200-
250 g in body weight) were selected in a randomized manner and subcutaneously 
injected with the Sugen5416 (20 mg/kg body weight) solution in the neck. Immediately 
after the injection, animals were exposed to hypoxia (10% O2) in the ventilated hypoxia 
chamber for three weeks, followed by re-exposure to normoxia for another two weeks. 
Control animals, which were injected with the same volume of saline, were kept in 
normoxic conditions for the same duration. Hemodynamic studies and tissue freezing 
occurred at the end of treatment. 
 Experimental groups and treatment 
Animals for the pirfenidone experiment were divided into three groups. Group I served 
as normal control rats, which were injected with sterile saline plus normoxia and were 
fed ad libitum with rodent laboratory chow. Group II served as PAH rats, which were 
injected with Sugen5416 plus hypoxia and were fed ad libitum with rodent laboratory 
chow. Group III served as the treatment group where hypoxia+Sugen5416 rats were fed 
with the same rodent laboratory chow with 0.5%(w/w) pirfenidone from day 21 to day 35. 
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Pirfenidone was mixed with the laboratory chow (the ratio is 0.5% weight of pirfenidone 
to 99.5% weight of chow) in a planetary mixer and was stored at 4°C. 
Animals for the nintedanib experiment were also divided into three groups. Group I 
served as normal control rats; they received injections of sterile saline plus normoxia and 
received vehicle (methylcellulose) alone. Group II served as PAH rats that received 
injections of Sugen5416 plus hypoxia and were given vehicle (methylcellulose) alone. 
Finally, group III served as the treatment group where the hypoxia+Sugen5416 rats 
received nintedanib at 50mg/kg of their body weight from day 21 to day 35. Nintedanib 
was prepared fresh in methylcellulose at 50mg/ml and administrated per os with a 
gavage needle in the same manner.   
 
Figure 7. Schedule of treatment in PH rat model. 
 Echocardiography 
The noninvasive measurement of several functional and morphometric parameters 
was performed by echocardiography, as described previously [109]. The rat was 
anesthetized with isoflurane and kept in a supine position on a heating platform. The 
limbs were tamped to ECG electrodes. Echocardiographic images were acquired with a 
VEVO 2100 high-resolution imaging system equipped with MicroScan linear array 
transducers, and the following parameters were analyzed: 
 -Right ventricle internal diameter (RVID) is the distance between the inner linings of 
the right ventricle free wall to the inner lining of the interventricular septum towards the 
right ventricle; it is measured in millimeters and serves as a parameter of right ventricle 
hypertrophy and dilatation. 
-Stroke volume (SV) is the volume of blood ejected by the ventricle during each 
contraction. 
-Cardiac output (CO) is the volume of blood ejected from the ventricle into the 
circulation per minute. Cardiac output equals SV multiplied by heart rate. The unit of 
measurement is liters/minute in humans and milliliters/minute in rodents.   
-Cardiac index (CI) is the ratio of cardiac output per 100 grams of the body; it 
estimates the performance of cardiac output according to the size of the body.   
 Surgical preparation and hemodynamic measurements 
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At the end of treatment, the rats were anesthetized with isoflurane, followed by an 
intramuscular (i.m.) injection of heparin (50 IU/kg body mass) to measure the 
hemodynamic parameters. The rats were then tracheotomized and ventilated at a 
frequency of 60 breaths/min, with a positive end expiratory pressure of 1 cm H2O 
throughout. Right ventricle systolic pressure (RVSP) is nearly equivalent to pulmonary 
artery systolic pressure in ideal conditions. To measure right ventricular systolic pressure 
(RVSP), a right heart catheter (PE 50 tube) was inserted through the right jugular vein, 
and to measure arterial pressure, a polyethylene catheter was inserted into the left 
carotid artery [110]. The computer software Labtech Notebook Runtime version 9.02 was 
used to record the pressure for five to ten minutes. 
 Lung tissue harvest and preparation 
After the hemodynamic measurements, whole lungs were flushed through the 
pulmonary artery with saline to remove red cells. The right lobe was snap frozen in liquid 
nitrogen and stored at -80º C for molecular biology assessment, while left lobes were 
perfused under 22 cmH2O of pressure through the pulmonary artery with 3.5 to 3.7 % 
formalin, and immersed in formalin for 24 hours. Formalin-fixed lung tissue samples were 
transferred to embedding cassettes and stored in phosphate-buffered saline (PBS). The 
dehydration was performed overnight in the Leica ASP300S tissue processor. The next 
day, the lung tissues were embedded in 65°C warmed paraffin with a heated Leica 
paraffin embedding module. The paraffin-embedded lung tissues were then cooled for 
hardening on a Leica cooling plate, sectioned to three-μm thick sections on the Leica 
fully-automated rotation microtome, and mounted on positively charged glass slides. 
Finally, lung tissue sections were dried on a Leica heating plate at 40°C and incubated 
at 37° C (for 12 hours) in a drying oven. 
 Medial wall thickness, neointima/media ratio and occlusion of vessels 
To assess pulmonary vascular remodeling, the medial wall thickness was determined, 
and the neointima/media wall ratio analysis was performed as previously published and 
described [109]. The media wall thickness of pulmonary vessels is defined as the 
distance between the internal elastic lamina and external elastic lamina. The neointima 
wall thickness of pulmonary vessels is defined as the distance between the internal 
elastic lamina and lumen. Vessels were assessed for occlusive lesions and scored as: 
no evidence of neointimal formation (open), partial (<50%) luminal occlusion, and full-
luminal occlusion (closed). To measure the medial wall thickness, neointima/media ratio 
and occlusion of vessels, van Gieson's staining was used. The three-µm lung tissue 
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sections were deparaffinized and rehydrated. After overnight staining in Resorcin-
Fuchsin, the slides with the tissue sections were washed with water. The sections were 
immersed in Weigert's working solution of hematoxylin for five minutes, which was 
prepared by mixing an equal volume of Weigert's Iron Hematoxylin A and Weigert's Iron 
Hematoxylin B. The sections were washed with running water and then with aqua dest. 
After washing, the slides were immersed in Van Gieson solution for 10 minutes. The 
sections were dehydrated and immersed in xylol and coverslipped with mounting 
medium (Pertex®). Vessels with an outer diameter of 20 to 50µm were used for analysis. 
Elastic fibers and cell nuclei were stained dark blue or dark brown by the iron-
hematoxylin stain, and collagen and muscle fibers were stained red by the van Gies 
counterstain. The cytoplasm was stained yellow due to counterstain. Finally, a light 
microscope with Leica Qwin V3 computer-assisted image analysis software was used 
for analysis.  
 Immunohistochemistry   
The three-µm section of lung tissue was deparaffinized in xylene and rehydrated in a 
series of grade-decreasing ethanol solutions followed by PBS. Antigen retrieval was 
achieved with a citrate buffer 20 times for 20 minutes. The endogenous peroxidase 
activity of the tissue was blocked using a freshly prepared solution of 30% hydrogen 
peroxide (H2O2) and methanol in a 1:1 ratio. The slides were then incubated again in 
proteinase K at RT for 15 minutes. After washing, the slides were incubated with 10% 
BSA, and then washed with 1x PBS and incubated with 2.5% normal horse serum for 30 
minutes. The slides were incubated with the primary antibody CD68 (1:100) or PCNA 
(1:100) overnight at 4°C. After washing with 1x PBS, the corresponding secondary 
antibody conjugated with HRP was applied for 30 min. After washing, the color was 
developed with the NovaRED substrate, followed by counterstaining with hematoxylin 
and dehydration. The procedure was completed by covering the slide with mounting 
medium and pulling the coverslip. The positive cells appeared brown or red in the light 
microscope and were examined under a Leica DM 2500 microscope using Leica QWin 
V3 imaging software.  
 Polymerase chain reaction (PCR) 
 RNA isolation 
The total RNA from the hPASMCs and lung tissue were isolated by using the Qiagen 
RNeasy Mini kit. The procedures were followed according to the manufacturer’s 
instructions. For hPASMCs, the cell medium was aspirated and cells were washed twice 
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with DPBS. Then, 350µL of Buffer RLT+-ME was applied to the cell-culture dish for five 
minutes. Cell lysate was scraped and collected for next step. For lung tissue, appropriate 
amount of tissue (30mg) and beads, and 600µL of RLT+-ME were added to a 
homogenizing tube and homogenized twice for 40 seconds in a rotor-stator 
homogenizer. The tubes were then centrifuged for three minutes at the maximum speed 
(14,000 rpm) and the supernatant was collected for next procedure.  
Cells lysate or supernatants from tissue were centrifuged for two minutes at 13,600 
rpm in an QIAshredder spin column. An equal volume of 70% ethanol was added to the 
previous supernatant, mixed well, and transferred into an RNeasy mini column and 
centrifuged at 10,000 rpm for 20 seconds. Three hundred and fifty µL of Buffer RW1 was 
added to the RNeasy mini column and centrifuged at 10,000 rpm for 20 seconds. The 
flow through was discarded, and 80µL of DNase+RDD buffer was added to the RNeasy 
mini column and incubated at RT for 15 minutes. Three hundred and fifty µL of Buffer 
RW1 was added and centrifuged at 10,000rpm for 20 seconds, and the flow through was 
discarded. In addition, 500µL of RPE buffer was added and centrifuged at 10,000 rpm 
for 20 seconds. The flow through was discarded. For elution, 50µL of RNase-free water 
was added directly to the membrane and centrifuged at 10,000 rpm for one minute. The 
quality and concentration of total RNA was measured with a NanoDrop 
spectrophotometer and the RNA was stored at -80°C. 
 Reverse transcription - polymerase chain reaction (RT-PCR) 
cDNA was synthesized by RT-PCR using the Bio-Rad iScript cDNA synthesis kit 
according to the manufacturer’s instructions.  One µg of RNA in 20 µl of the master mix 
was used per reaction (Table 4). The reverse transcription was performed in a 
thermocycler and the program is shown in Table 5. The cDNA was stored at -20°C. 
Table 4 RT-PCR components 
Components Volume per reaction 
5x iScript reaction mix  4 µl 
iScript reverse transcriptase 1 µl 
RNA (1µg)  up to the concentration 
Nuclease-free water to the final volume (20 µl) 
Total mix volume 20 µl 
 
Table 5 RT-PCR thermocycler program 
Program Temperature Time 
Annealing  25°C 5 min 
Incubation  42°C 30 min 
    Thermal inactivation of reverse transcriptase   85°C 5 min 
Hold at                                                                  4°C 
 Quantitative real-time polymerase chain reaction (qPCR) 
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The exon-spanning primer pairs for human and rat genes were designed using the 
NCBI/ Primer-BLAST and are shown in Table 3. The product size is within the range of 
100 bp - 300 bp. Furthermore, qPCR was performed on a Mx3000P® QPCR system 
machine using an iTaqTM SYBR® Green Supermix kit and procedures were followed 
according to manufacturer’s instructions (Table 6, 7). The nuclease free water was used 
as negative control instead of cDNA.  
Table 6 Quantitative PCR reaction components 
qRT- PCR reaction component Volume per reaction 
cDNA template 2 µl 
Forward primer 10 µM 0.5 µl 
Reverse primer 10 µM 0.5 µl 
iTaq SYBR Green supermix (2X) 10 µl 
Nuclease-free water 6 µl 
Total volume 20 µl 
 
Table 7 Quantitative PCR program 
  Temperature Time Cycle 
Activation 95°C 10 min     1 
Denaturation 95°C 30 sec   
    40 Annealing 58°C 30 sec 
Extension 72°C 30 sec 
Denaturing 95°C 1 min  
Dissociation curve 55-95°C indefinite     1 
Hold 4°C indefinite     1   
 
The dissociation curve was generated by MxPro™ QPCR software and used to 
ensure single product amplification. The threshold cycle (Ct values) was determined for 
each gene. The Ct values of the target genes were normalized to that of the 
housekeeping hypoxanthine-guanine phosphoribosyl transferase (HPRT) using the 
formula ΔCt = Ctreference – Cttarget. The ΔCt of the control sample was then subtracted from 
a treated sample, providing the ΔΔCt. mRNA expression was analyzed with the 2−ΔΔCT 
method that represents the fold change of the treated target gene relative to the control. 
Each reaction was run in duplicate and repeated three times independently. 
 Western blotting 
 Protein isolation 
The total protein was extracted in RIPA buffer (containing 1x TBS, 1% Nonidet P-40, 
0.1% SDS, 0.5% sodium deoxycholate, and 0.004% sodium azide) according to the 
manufacturer’s instructions. Proteinase inhibitor cocktail, sodium orthovanadate, and 
PMSF were added to RIPA immediately before use. In addition, 100 mg of lung tissue 
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was homogenized in 600 μl of RIPA or 1×106 hPASMCs in 300 μl of RIPA was 
centrifuged at 12,000 rpm for 30 minutes at 4°C and the supernatants were kept at -
80°C. 
Table 8 RIPA buffer recipe 
Component of RIPA Final concentration 
RIPA buffer 1x 
Protease inhibitor cocktail 1x 
Sodium orthovanadate 1% 
PMSF 1% 
 Protein concentration measurement 
Protein concentration was determined with a Bio-Rad DC protein assay according to 
the manufacturer’s instructions for the microplate assay protocol. This assay method is 
a well-documented Lowry assay with slight improvements. The assay is based on the 
reaction of protein with an alkaline copper tartrate solution and Folin reagent. There are 
two steps which lead to color development: the reaction between protein and copper in 
an alkaline medium (Reagent A) and the subsequent reduction of Folin (Reagent B) 
reagent by the copper-treated protein. A series of bovine serum albumin (BSA) 
concentration, 0.25- 0.5- 1- 2 mg/ml, was used as a standard for the protein from cell 
lysates, and 1.25- 2.5- 5- 10- 20 mg/ml, were used as a standard for the protein from 
tissue lysates. The protein samples were pre-diluted to the range of the standard and 
the protein concentration of each sample was estimated in duplicate. After developing 
the blue color, samples were measured at 750 nm using a Tecan microplate reader. The 
final protein concentration was calculated with accompanying Magellan™ software using 
the linear regression method.  
 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
Protein samples with equal concentration were mixed with 5× SDS gel loading buffer 
at a ratio of 4:1 (v/v) and denatured at 100°C for five minutes.  
                             Table 9 5×SDS gel-loading buffer recipe 
5×SDS gel-loading buffer component Final concentration 
Tris-HCl (2 M, pH 6.8) 375 mM 
SDS 10% (w/v) 
Glycerol 50% (v/v) 
β-Mercaptoethanol 12.5% (v/v) 
Bromophenol blue 0.02% (w/v) 
 
Polyacrylamide gels were prepared according to the following procedure: The space 
between the glass plates was filled with separating gel mixture, and 2-propanol was 
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poured on top of this mixture until the gels polymerized. After 30 minutes, water from the 
resolving gel was removed and a 6% stacking gel solution was added. A comb was 
inserted, and polymerization lasted 30 minutes. The protocols for the SDS-PAGE gels 
are listed in table 10 and table 11. Finally, protein samples or dual protein markers were 
loaded into the lanes of SDS-PAGE gel and run at 100-130V for two hours to separate. 
The buffers are listed in table 12. 
Table 10 Separation gel (8% and 10%) 
Gel components Final concentration 
 8% 10% 
Tris-Cl (1.5 M, pH 8.9) 375 mM 375 mM 
Acrylamide 30% (w/v) 8% (w/v) 10% (w/v) 
SDS 10% (w/v) 0.1% (w/v) 0.1% (w/v) 
APS 10% (w/v) 0.05% (w/v) 0.05% (w/v) 
TEMED 0.1% (w/v) 0.1% (w/v) 
Water up to the final volume   
 
Table 11 Stacking gel (6%) 
Gel components  Final concentration 
Tris-Cl (0.5 M, pH 6.8)  125 mM 
Acrylamide 30% (w/v)  6% (w/v) 
SDS 10% (w/v)  0.1% (w/v) 
APS 10% (w/v)  0.05% (w/v) 
TEMED  0.1% (w/v) 
Water up to the final volume   
 
Table 12 Running buffer recipe 
Running buffer component Final concentration 
Tris-HCl 25 mM 
Glycine 192 mM 
SDS 0.1% (w/v) 
                              
 Transfer of proteins and staining 
The proteins that were separated with the SDS-PAGE were transferred to a 
nitrocellulose membrane at 100V for one hour using a blotting apparatus. The 
membranes were blocked with 5% non-fat milk for one hour at RT and probed with 
primary antibodies (diluted in TBST with 5% BSA) at 4°C overnight. After washing three 
times with TBS containing 0.1% Tween-20, horseradish peroxidase (HRP)-conjugated 
secondary antibodies (diluted in TBST with 5% BSA) were applied for one hour at RT. 
After washing, the blots were developed using an enhanced chemiluminescence (ECL) 
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kit. The blots were captured by X-ray films and the intensity of bands was quantified by 
densitometry. The antibodies are listed in table 2. 
Table 13 Blotting buffer recipe 
Running buffer component Final concentration 
Tris-HCl 50 mM 
Glycine 40 mM 
Methanol 20% (w/v) 
 
Table 14 TBST buffer (pH 7.6) recipe 
TBST buffer (pH 7.6) component Final concentration 
Tris-HCl 20 mM 
NaCl 150 mM 
Tween 0.1% (v/v) 
 
 Statistics 
GraphPad Prism® v6.05 was used for all statistical analysis, and data are expressed 
as means ± SEM when appropriate. Significance was assessed using unpaired t tests 
(when two groups analyzed) or one-way ANOVA-Newman-Keuls tests (for more than 
two groups); P < 0.05 was considered significant. 
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4 RESULTS 
4.1 The effect of PDGF-BB on proliferation of human pulmonary arterial smooth 
muscle cells 
Growth factors such as PDGFs are potent mitogens and chemoattractants for 
vascular cells. These growth factors play important roles in the remodeling process of 
PAH development by controlling many cellular functions and processes, including 
cellular proliferation, migration, and extracellular matrix deposition [7,17].  
A pilot experiment for PDGF-BB induced hPASMCs proliferation was conducted with 
different concentrations ranging from 0 to 100ng/ml. In this experiment, PDGF-BB 
induced the proliferation of hPASMCs in a dose-response manner (Figure 8). Based on 
this pilot study, 30ng/ml was used as the concentration for PDGF-BB in the following in 
vitro experiments. 
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Figure 8. The effect of PDGF-BB on proliferation of human pulmonary arterial smooth 
muscle cells. 
Human PASMCs proliferation was induced by PDGF-BB incubation for 24hours with different 
concentrations ranging from 0 ng/ml to 100 ng/ml. The proliferation of hPASMCs was assayed by 
the incorporation of BrdU into newly synthesized DNA. Results are expressed as mean ± SEM; 
n=6.  PDGF, platelet derived growth factor. 
4.2 The effect of pirfenidone on the proliferation of human pulmonary arterial 
smooth muscle cells  
To determine the effect of pirfenidone on growth-factor-induced hPASMCs 
proliferation, PDGF-BB and multi-growth factors (MGF, including FBS, hEGF, hFGF-B, 
and insulin) were employed to stimulate the proliferation of hPASMCs. As shown in figure 
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9A, PDGF-BB induced proliferation of hPASMCs was inhibited by pirfenidone in a dose-
response manner. However, hPASMCs proliferation which was induced by MGF was 
only inhibited by the high dose of pirfenidone (1mg/ml), and not the low or middle dose 
(Figure 9B). The viability of hPASMCs was also checked with the WST-1 kit and no cell 
toxicity was observed after pirfenidone incubation. Therefore, the inhibitory effect of 
proliferation for pirfenidone was not due to cytotoxicity.    
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Figure 8. The effect of pirfenidone on the proliferation of human pulmonary arterial 
smooth muscle cells. 
Human PASMCs was stimulated by 30ng/ml of PDGF-BB (A) or MGF (B) for 24hours to induce 
proliferation in the absence or presence pirfenindone. The proliferation of hPASMCs was assayed 
by the incorporation of BrdU into newly synthesized DNA. C, the viability of hPASMCs was 
checked by WST-1 method after 24 hours of pirfenidone incubation. Results are expressed as 
mean ± SEM; n=3 independent experiments; **P<0.01. PDGF, platelet derived growth factor; 
PFD, pirfenidone; MGF, multiple growth factors (including FBS, hEGF, hFGF-B, and insulin). 
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4.3 The effect of pirfenidone on the PDGF-BB-induced migration of human 
pulmonary arterial smooth muscle cells 
The role of pirfenidone on cell migration was investigated by incubating hPASMCs 
with PDGF-BB in the absence and presence of pirfenidone (0.1, 0.3, 1mg/ml) for 24 
hours, after which the cell migration was counted. As shown in figure 10, PDGF-BB 
significantly induced hPASMCs migration compared to the control group, and the high 
dose of pirfenidone inhibited PDGF-BB induced hPASMCs migration. However, the 
middle and low dose of pirfenidone did not demonstrate any inhibitory effect on 
hPASMCs migration. 
A                                                               B                                                
          
         Control                       PDGF-BB+PFD0.3mg/ml 
                                    
      PDGF-BB+Veh               PDGF-BB+PFD1mg/ml 
 
PDGF-BB+PFD0.1mg/ml                                                            
 
Figure 9. Effect of pirfenidone on PDGF-BB–induced migration of human pulmonary 
arterial smooth muscle cells. 
A, representative picture of hPASMCs migration, scale bars = 100µm; B, cell number of hPASMCs 
migration. Human PASMCs were stimulated with 30 ng/ml of PDGF-BB for 24h to induce 
migration in the absence or presence of pirfenidone. Migration result was expressed as the 
number of migrated cells. Results are expressed as mean ± SEM; n=3-5 independent 
experiments. **P<0.01. PDGF, platelet derived growth factor; PDF, pirfenidone.  
4.4 The effect of pirfenidone on PDGF-BB-induced collagen synthesis and the 
secretion of human pulmonary arterial smooth muscle cells 
To investigate the effect of pirfenidone on collagen deposition in hPASMCs, the 
collagen I protein expression was investigated in the hPASMCs homogenate by western 
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blot and the collagen secretion of hPASMCs in the medium was observed with the Sircol 
method. Collagen I protein level was increased in PAMSCs after PDGF-BB incubation 
for 24 hours, and this increase was attenuated by pirfenidone, as shown in figure 11A. 
Moreover, collagen in the medium significantly increased after PDGF-BB incubation for 
72 hours, and pirfenidone incubation decreased the content of collagen in the medium 
in a dose response manner (Figure 11B). The alteration in levels of collagen protein in 
the culture medium is consistent with the levels of intracellular collagen 1 protein, 
suggesting that collagen is secreted into extracellular space.     
A                                                                      B    
 
Figure 10. The effect of pirfenidone on PDGF-BB induced collagen synthesis and the 
secretion of human pulmonary arterial smooth muscle cells.  
Human PASMCs were incubated with 30ng/ml of PDGF-BB in the absence and presence 
pirfenidone. A, representative western blot picture of collagen1. The total protein was extracted 
from hPASMCs 24 hours after incubation and collagen1 expression was checked by western blot. 
B, the soluble collagen1 level in the medium. The collagen secretion of hPASMCs in the medium 
was measured by the Sircol method 72 hours after incubation. Results are expressed as mean ± 
SEM; n=3~5 independent experiments, *P<0.05, **P<0.01. PDGF, platelet derived growth factor; 
PFD, pirfenidone. 
4.5 The effect of pirfenidone on interleukin mRNA expression in human 
pulmonary arterial smooth muscle cells 
Since accumulating evidence indicates that inflammation is involved in the 
development of PAH, the efficacy of pirfenidone for PDGF-BB-induced inflammatory 
cytokine interleukins mRNA expression was investigated. As shown in figure 12, the 
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increased levels of IL-1β and IL-6 induced by PDGF-BB were blocked by pirfenidone in 
a dose-response manner.  
             A                                                        B 
                   
Figure 11. The effect of pirfenidone on the PDGF-BB-induced mRNA expression of 
interleukins in human pulmonary arterial smooth muscle cells. 
A, IL-1β mRNA expression; B, IL-6 mRNA expression. Human PASMCs were incubated with 
30ng/ml of PDGF-BB in the absence and presence pirfenidone for 24 hours. The RNA was 
isolated from the hPASMCs homogenate, cDNA was synthesized by RT-PCR and measured by 
qPCR. The results are expressed as mean ± SEM; n=3 independent experiments, *P<0.05; 
**P<0.01. PDGF, platelet derived growth factor; PFD, pirfenidone; IL, interleukin. 
4.6 The effect of pirfenidone on the phosphorylation of PDGFRβ, PI3K, and AKT 
in human pulmonary arterial smooth muscle cells 
Although pirfenidone was approved for IPF treatment in clinics in 2008, the precise 
action of mechanism is still unknown. To explore the mechanism of pirfenidone on 
hPASMCs’ collagen synthesis, proliferation, and migration, the phosphorylation of the 
PDGFR-β, PI3K, and Akt signaling pathway was examined. As shown in figure 13, 
PDGF-BB stimulation led to obvious phosphorylation of PDGFR-β, PI3K, and Akt in 
hASMCs. Pirfenidone inhibited all the phosphorylation that was induced by PDGF-BB. 
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Figure 12. The effect of pirfenidone on the phosphorylation of PDGFR-β, PI3K, and Akt in 
human pulmonary arterial smooth muscle cells.  
Human PASMCs were stimulated with 30ng/ml of PDGF-BB in the absence and presence of 
pirfenidone. The total protein was extracted from hPASMCs homogenate and checked by western 
blot. The total and phosphorylation of PDGFR-β and PI3K expression were assayed 15 mins after 
stimulation; the total and phosphorylation of Akt expression were checked 30 mins after 
stimulation. n=3 independent experiments. PDGF, platelet derived growth factor; PFD, 
pirfenidone. 
4.7 The effect of pirfenidone on right ventricular systolic pressure and 
hypertrophy in SuHx rats 
Considering the promising in vitro effects of pirfenidone, the SuHx rat’s model of PH 
was employed to investigate the efficacy of pirfenidone in vivo. After injection of the 
VEGF receptor inhibitor with exposure to chronic hypoxia for three weeks followed by re-
exposure to normoxia for another two weeks, rats exhibited significantly elevated right 
ventricular systolic pressure (RVSP) compared to normoxic control rats, as shown in 
figure 14 A. Pirfenidone reduced this elevated RVSP to 40.5 ± 4.2 mmHg (p<0.05, versus 
vehicle, Figure 14A). 
The Fulton index, which is defined as RV/(LV+Septum), and right ventricular internal 
diameter (RVID) were examined to demonstrate the RV hypertrophy and dilatation. The 
Fulton index, a marker for right ventricular hypertrophy, significantly increased in PAH 
model rats (Figure 14B), and was lower in the pirfenidone treatment group (p<0.01, 
versus vehicle-treated rats, Figure 14B). Furthermore, RVID in SuHx rats also 
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significantly increased compared to normoxia control rats and was reduced to 4.36 ± 
0.20 mm by treatment of pirfenidone (p<0.05, versus vehicle-treated rats, Figure 14C). 
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Figure 13. The effect of pirfenidone on RV systolic pressure and hypertrophy in SuHx rats. 
A, right ventricle systolic pressure; B, ratio of RV to left ventricular, RV/(LV+S); C, right ventricle 
internal diameter of different group. SuHx rats model was induced by subcutaneously injection 
with Sugen5416 and exposure to hypoxia for three weeks, followed by re-exposure to normoxia 
for another two weeks. Control animals, which were injected with the same volume of saline, were 
kept in normoxic conditions for the same duration. SuHx rats were either fed standard chow or 
0.5% pirfenidone mixed in chow from day 21 to day 35. Control animals received standard diet. 
The results are expressed as mean ± SEM, n=6~8 rats per group, *P<0.05 and **P<0.01. PFD, 
pirfenidone; NOX, normoxia; RVSP, right ventricle systolic pressure; RVID, right ventricle internal 
diameter; RV, right ventricle; LV, left ventricle; S, septum.  
4.8 The effect of pirfenidone on right ventricle function in SuHx rats 
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Right ventricle function is impaired in PH patients. Stroke volume, cardiac output 
(CO), and cardiac index (CI) were measured to evaluate the function of the right ventricle 
in experimental PAH. Consistent with the results of RV hypertrophy, SuHx rats showed 
RV dysfunction with decreased stroke volume, cardiac output, and cardiac index. 
Moreover, pirfenidone improved the RV function by increasing the stroke volume, cardiac 
output, and cardiac index of the right ventricle (all p<0.01, versus vehicle Figure 15A, B, 
and C). 
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Figure 14. The effect of pirfenidone on RV function in SuHx rats. 
A, stroke volume; B, cardiac output; and C, cardiac index of different groups. SuHx rats model 
was induced by injection with the Sugen5416 and hypoxia exposure for three weeks, followed by 
re-exposure to normoxia for another two weeks. Control animals, which were injected with saline, 
were kept in normoxic conditions. SuHx rats were either fed standard chow or 0.5% pirfenidone 
mixed in chow from day 21 to day 35. Control animals received standard diet. The results are 
expressed as mean ± SEM, n=6~8 rats per group, *P<0.05, **P<0.01. PFD, pirfenidone. NOX, 
normoxia; SV, stroke volume; CO, cardiac output; CI, cardiac index.  
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4.9 The effect of pirfenidone on vascular remodeling in SuHx rats 
Neointima formation, media wall hypertrophy, and occlusion in small pulmonary 
vessels are key features of vascular remodeling in the development of PH. Similar to RV 
function and hypertrophy, the SuHx animal model demonstrated severe vascular 
remodeling which was shown by an increased neointima to media wall ratio and media 
wall thickness of the small pulmonary vessels (20-50 µm in diameter). The proportion of 
fully closed arteries was also remarkably increased and non-occlusion vessels were 
significantly decreased in SuHx rats. Pirfenidone attenuated the development of vascular 
remodeling and decreased the neointima to media wall ratio (p<0.01, versus vehicle; 
Figure 16A) and the media wall thickness (p<0.05, versus to vehicle, Figure 16B). The 
ratio of fully closed arteries was decreased, and the ratio of non-occlusion vessels was 
elevated after treatment by pirfenidone (p<0.05 or p<0.01, versus to vehicle, Figure 16C). 
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Figure 15. The effect of pirfenidone on vascular remodeling in SuHx rats. 
A, neointima/media wall ratio; B media wall thickness; C, occlusion of vessels (20-50 µm in 
diameter) of different groups; D, representative images for vascular remodeling, scale 
bars = 20µm. SuHx rats model was induced by subcutaneously injection with the Sugen5416 and 
exposure to hypoxia for three weeks, followed by re-exposure to normoxia for another two weeks. 
Control animals, which were injected with the same volume of saline, were kept in normoxic 
conditions for the same duration. SuHx rats were either fed standard chow or 0.5% pirfenidone 
mixed in chow from day 21 to day 35. Control animals received standard diet. The results are 
expressed as mean ± SEM, n=6~8 rats per group, *P<0.05 and **P<0.01.  PFD, pirfenidone. 
NOX, normoxia.  
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4.10 The effect of pirfenidone on pulmonary vascular cell proliferation in SuHx 
rats  
The proliferating cell nuclear antigen is a key factor in DNA replication and cell cycle 
regulation. To further evaluate the inhibitory effect of pirfenidone on vascular cell 
proliferation in the development of vascular remodeling, immunohistochemical staining 
for PCNA was performed. Immunohistochemistry results demonstrate that significantly 
increased PCNA positive cells were detected in vessels from SuHx rats. In addition, the 
PCNA positive cells remarkably decreased after treatment with pirfenidone (p<0.01, 
versus to vehicle, Figure 17B)  
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Figure 16. The effect of pirfenidone on pulmonary vascular cell proliferation. 
A, representative images of PCNA staining, where the arrow indicates the PCNA positive cell 
scale bars = 20µm; B, PCNA positive cells per vessels (20-50 µm in diameter). SuHx rats model 
was induced by subcutaneously injection with the Sugen5416 and exposure to hypoxia for three 
weeks, followed by re-exposure to normoxia for another two weeks. Control animals, which were 
injected with the same volume of saline, were kept in normoxic conditions for the same duration. 
SuHx rats were either fed standard chow or 0.5% pirfenidone mixed in chow from day 21 to day 
35. Control animals received standard diet. The results are expressed as mean ± SEM, n=6 rats 
per group, **P<0.01. PCNA, proliferating cell nuclear antigen; PFD, pirfenidone. NOX, normoxia.   
4.11 The effect of pirfenidone on collagen expression in lung tissue of SuHx rats 
SuHx+Vehicle 
SuHx+PFD 
NOX Control 
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The antifibrotic effect of pirfenidone was measured by assessing the collagen level 
on mRNA and protein expression. The mRNA expression of collagen 1a1 and 3a1 were 
both elevated in the lung tissue from SuHX rats, and this increased mRNA expression 
was reversed by pirfenidone, as shown in figure 18. Likewise, a higher protein expression 
of collagen 1 was detected in SuHx rat compared to the normoxia controls, and 
pirfenidone treatment significantly attenuated the collagen 1 expression (P<0.05 versus 
vehicle, Figure 18D).   
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Figure 17. The effect of pirfenidone on interleukin mRNA expression lung tissue of in SuHx 
rats. 
The protein and mRNA were extracted from lung tissue and collagen expression was checked by 
qPCR and western blot. A, collagen 1a1 mRNA expression; B, collagen 3a1 mRNA expression; 
C, western blots against collagen 1 with pan-actin as a loading control; D, densitometric 
quantification of phosphorylation collagen 1 expression is shown as a ratio by normalization to 
pan-actin in a bar graph. *P<0.05, **P<0.01. n=4~6 in each group. Values are expressed as mean 
± SEM. PFD, pirfenidone; NOX, normoxia.   
pan actin
Collagen-1
SuHx+
Placebo
NOX
Control
 SuHx+
Pirfeinidone
RESULTS 
47 
 
4.12 The effect of pirfenidone on inflammation in small pulmonary vessels of 
SuHx rats 
The anti-inflammatory effect of pirfenidone was assessed by detecting macrophage 
infiltration in the small pulmonary vessels. Macrophage infiltration in the vessels was 
detected by immunochemical staining with CD68, a valuable marker to identify 
macrophages. More CD68 positive cells were present in the small pulmonary vessels, 
and pirfenidone treatment significantly decreased this macrophage infiltration in the 
vessels (P<0.05 versus vehicle, Figure 19B). 
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Figure 18. The effect of pirfenidone on inflammation in small pulmonary vessels of SuHx 
rats. 
A, representative images of CD68 staining, where the arrow indicates the CD68 positive cell, 
scale bars = 20µm; B, CD68 positive cells per vessels (20-50 µm in diameter). SuHx rats model 
was induced by subcutaneously injection with the Sugen5416 and exposure to hypoxia for three 
weeks, followed by re-exposure to normoxia for another two weeks. Control animals, which were 
injected with the same volume of saline, were kept in normoxic conditions for the same duration. 
SuHx rats were either fed standard chow or 0.5% pirfenidone mixed in chow from day 21 to day 
35. Control animals received standard diet. The results are expressed as mean ± SEM, n=6 rats 
per group, *P<0.05 and **P<0.01.  PFD, pirfenidone; NOX, normoxia.     
4.13 The effect of pirfenidone on interleukin mRNA expression in lung tissue of 
SuHx rats 
Interleukin mRNA expression in lung tissue was measured by RT-PCR as another 
index for the anti-inflammation efficacy of pirfenidone. Levels of IL-1β and IL-6 mRNA 
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from SuHx rats were much higher than those of normoxia control rats. As shown in figure 
20, IL-1β and IL-6 expression were inhibited by pirfenidone treatment (both P<0.05 
versus Vehicle).            
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Figure 19. The effect of pirfenidone on interleukin mRNA expression in lung tissue of SuHx 
rats. 
A, IL-1β mRNA expression; B, IL-6 mRNA expression. The mRNA was extracted from lung tissue 
and interleukin expression was checked by qPCR. SuHx rats model was induced by 
subcutaneously injection with the Sugen5416 and exposure to hypoxia for three weeks, followed 
by re-exposure to normoxia for another two weeks. Control animals, which were injected with the 
same volume of saline, were kept in normoxic conditions for the same duration. SuHx rats were 
either fed standard chow or 0.5% pirfenidone mixed in chow from day 21 to day 35. Control 
animals received standard diet. The results are expressed as mean ± SEM, n=6 in each group, 
*P<0.05 and **P< 0.01.  PFD, pirfenidone; NOX, normoxia; IL, interleukin.   
4.14 The effect of pirfenidone on the phosphorylation of PDGFR-β and AKT in 
lung tissue of SuHx rats 
The in vitro data demonstrated that pirfenidone inhibited all phosphorylation of 
PDGFR-β, PI3K, and AKT that was induced by PDGF-BB. To elucidate the mechanism 
of pirfenidone acting on PAH development, the PDGFR-β and AKT signaling pathway in 
the lung tissue was investigated further. The Western blot results demonstrated a higher 
level of PDGFR-β and AKT phosphorylation in the lung tissue lysate of SuHx rats than 
in normoxia controls. The phosphorylation of both PDGFR-β and AKT was inhibited by 
pirfenidone, as shown in figure 21 (both p<0.05). 
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Figure 20. The effect of pirfenidone on the phosphorylation of PDGFR-β and Akt in lung 
tissue of SuHx rats.  
A, western blots against pPDGFR-β with PDGFR-β as a loading control; B, western blots against 
pAkt with Akt as a loading control; C, densitometric quantification of phosphorylation PDGFR-β 
expression is shown as a ratio by normalization to PDGFR-β in a bar graph; D, densitometric 
quantification of phosphorylation Akt expression is shown as a ratio by normalization to Akt in a 
bar graph. The protein was extracted from lung tissue and PDGFR-β and Akt expression was 
checked by western blot. SuHx rats model was induced by subcutaneously injection with the 
Sugen5416 and exposure to hypoxia for three weeks, followed by re-exposure to normoxia for 
another two weeks. Control animals, which were injected with the same volume of saline, were 
kept in normoxic conditions for the same duration. SuHx rats were either fed standard chow or 
0.5% pirfenidone mixed in chow from day 21 to day 35. Control animals received standard diet. 
Values are expressed as means ± SEM, n=4 in each group, *P<0.05, **P<0.01. PFD, pirfenidone; 
NOX, normoxia.   
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4.15 The effect of nintedanib on the proliferation of human pulmonary arterial 
smooth muscle cells  
In addition to Pirfenidone, another drug (nintedanib) was approved for IPF treatment. 
The effects of nintedanib were investigated in vitro as well as those of pirfenidone. To 
determine the effect of nintedanib on growth-factor-induced hPASMCs proliferation, 
PDGF-BB and multi-growth factors (MGF) were employed to stimulate the proliferation 
of hPASMCs. As shown in figure 22 (next page), the proliferation of hPASMCs, induced 
by PDGF-BB, was inhibited by nintedanib in a dose-response manner, and nintedanib 
did not show inhibitory effects on multiple-growth-factor-induced cell proliferation. The 
viability of hPASMCs was also determined using a WST-1 kit, and no cytotoxicity was 
observed after nintedanib incubation. These findings demonstrate that the inhibitory 
effect of hPASMC proliferation for nintedanib did not result from cytotoxicity. 
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Figure 21. The effect of nintedanib on the proliferation of human pulmonary arterial 
smooth muscle cells.  
Human PASMCs was induced by 30ng/ml of PDGF-BB (A) or MGF (B) for 24hours to induce 
proliferation in the absence or presence nintedanib. The proliferation of hPASMCs was assayed 
by the incorporation of BrdU into newly synthesized DNA. C, the viability of hPASMCs was 
checked by WST-1 method after 24 hours of nintedanib incubation. Results are expressed as 
mean ± SEM; n=3 independent experiments; **P<0.01. PDGF, platelet derived growth factor; Nin, 
nintedanib; MGF, multiple growth factors (including FBS, hEGF, hFGF-B, and insulin). 
4.16 The effect of nintedanib on the PDGF-BB–induced migration of human 
pulmonary arterial smooth muscle cells 
To investigate the role of nintedanib on PDGF-BB–induced cell migration, hPASMCs 
with PDGF-BB were also incubated in the absence and presence of nintedanib for 24 
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hours, after which the cell migration was counted. As shown in figure 23, the PDGF-BB-
induced migration of cells was inhibited by nintedanib in a dose-response manner. 
A                                                                    B 
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   PDGF+Nin 30nM                
Figure 22. The effect of nintedanib on the PDGF-BB-induced migration of human 
pulmonary arterial smooth muscle cells. 
A, representative picture of hPASMCs migration, scale bars = 100µm; B, cell number of hPASMCs 
migration. Human PASMCs were stimulated with 30 ng/ml of PDGF-BB for 24h to induce 
migration in the absence or presence of nintedanib. Migration result was expressed as the number 
of migrated cells. Results are expressed as means ± SEM; n=3-5 experiments, *P<0.05, **P<0.01. 
PDGF, platelet derived growth factor; Nin, nintedanib. 
4.17 The effect of nintedanib on PDGF-BB-induced collagen synthesis and 
secretion in human pulmonary arterial smooth muscle cells   
To further investigate the effect of nintedanib on collagen deposition, collagen I protein 
expression in hPASMCs homogenate was measured by western blot and collagen 
secretion in the medium with the Sircol method. The increased collagen I protein level, 
which was induced by PDGF-BB, was attenuated by nintedanib as shown in figure 24A. 
In parallel, nintedanib incubation decreased the content of collagen in the medium in a 
dose-response manner (Figure 24B). 
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Figure 23. The effect of nintedanib on PDGF-BB-induced collagen synthesis and the 
secretion of human pulmonary arterial smooth muscle cells.  
Human PASMCs were incubated with 30ng/ml of PDGF-BB in the absence and presence 
nintedanib. A, representative western blot picture of collagen1. The total protein was extracted 
from hPASMCs after 24hours incubation and collagen1 expression was checked by western blot. 
B, the soluble collagen1 level in the medium. The collagen secretion of hPASMCs in the medium 
was measured by the Sircol method 72 hours after incubation. Results are expressed as means 
± SEM; n=3~5 experiments. *P<0.05, **P<0.01. PDGF, platelet derived growth factor; Nin, 
nintedanib. 
4.18 The effect of nintedanib on interleukin mRNA expression in human 
pulmonary arterial smooth muscle cells 
To investigate the efficacy of nintedanib on PDGF-BB-induced inflammatory cytokine 
expression, interleukin mRNA expression was examined. As shown in figure 25, 
increases in levels of IL-1β and IL-6 induced by PDGF-BB were blocked by the presence 
of nintedanib.  
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                  A                                                           B                              
                   
Figure 24. The effect of nintedanib on the PDGF-BB-induced mRNA expression of 
interleukins in human pulmonary arterial smooth muscle cells. 
A, IL-1β mRNA expression, B, IL-6 mRNA expression. Human PASMCs were incubated with 
30ng/ml of PDGF-BB in the absence and presence nintedanib. The RNA was isolated from the 
hPASMCs homogenate, cDNA was synthesized by RT-PCR and measured by qPCR. Results 
are expressed as means ± SEM; n=3 independent experiments, *P<0.05, *P<0.01. PDGF, 
platelet derived growth factor; Nin, nintedanib; IL, interleukin. 
4.19 The effect of nintedanib on the phosphorylation of PDGFRβ, PI3K, and AKT 
in human pulmonary arterial smooth muscle cells 
To investigate the role of nintedanib on PDGF-BB-induced increases in collagen 
synthesis, proliferation, and migration, the phosphorylation of PDGFR-β, PI3K, and Akt 
signaling pathway was examined. As shown in figure 26, nintedanib reversed the PDGF-
BB-induced increases in the phosphorylation of PDGFRb, PI3K, and Akt. 
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Figure 25. The effect of nintedanib on the phosphorylation of PDGFR-β, PI3K, and Akt in 
human pulmonary arterial smooth muscle cells.   
Human PASMCs were incubated with 30ng/ml of PDGF-BB in the absence and presence 
nintedanib. The total protein was extracted from hPASMCs homogenate and checked by western 
blot. The total and phosphorylation of PDGFR-β and PI3K expression were assayed 15 minutes 
after stimulation with PDGF-BB; the total and phosphorylation of Akt expression were analyzed 
30 minutes after stimulation with PDGF-BB. n=3 independent experiments. PDGF, platelet 
derived growth factor; Nin, nintedanib. 
4.20 The effect of nintedanib on right ventricle systolic pressure and hypertrophy 
in SuHx rats 
Based on the promising in vitro results of nintedanib, the efficacy of nintedanib was 
also investigated with the SuHx rat model. The RVSP in SuHx rats was significantly 
elevated compared to normoxia control rats, as shown in figure 27A. Nintedanib did not 
show any inhibitory effects on RVSP, which was unexpected. The Fulton index and RVID 
in SuHx rats were also increased compared to normoxia control rats (Figure 27B and C), 
and there were no changes in RV hypertrophy after treatment with nintedanib.   
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Figure 26. The effect of nintedanib on hemodynamics in SuHx rats.  
A, right ventricle systolic pressure; B, ratio of RV to left ventricular, RV/(LV+S); C, right ventricle 
internal diameter of different group. SuHx rats model was induced by subcutaneously injection 
with the Sugen5416 and exposure to hypoxia for three weeks, followed by re-exposure to 
normoxia for another two weeks. Control animals, which were injected with the same volume of 
saline, were kept in normoxic conditions for the same duration. SuHx rats were either vehicle or 
50mg/kg nintedanib from day 21 to day 35. Control animals received vehicle only. Results are 
expressed as mean ± SEM, n=6~10 rats per group, **P< 0.01. Nin, nintedanib; NOX, normoxia; 
RVSP, right ventricle systolic pressure; RVID, right ventricle internal diameter; RV, right ventricle; 
LV, left ventricle; S, septum.  
4.21 The effect of nintedanib on RV function in SuHx rats 
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SuHx rats demonstrated impaired RV function, and nintedanib did not improve the 
SV, CO, or CI of the right ventricle (all p>0.05, versus to vehicle Figure 28A, B and C). 
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Figure 27. The effect of nintedanib on RV function in SuHx rats.  
A, stroke volume; B, cardiac output; C, cardiac index of different group. SuHx rats model was 
induced by subcutaneously injection with the Sugen5416 and exposure to hypoxia for three 
weeks, followed by re-exposure to normoxia for another two weeks. Control animals, which were 
injected with the same volume of saline, were kept in normoxic conditions for the same duration. 
SuHx rats were either vehicle or 50mg/kg nintedanib from day 21 to day 35. Control animals 
received vehicle only. The results are expressed as mean ± SEM, n=6~10 rats per group, 
**P<0.01. Nin, nintedanib; NOX, normoxia; SV, stroke volume; CO, cardiac output; CI, cardiac 
index.  
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4.22 The effect of nintedanib on vascular remodeling in SuHx rats 
SuHx rats demonstrated severe vascular remodeling, including an increased 
neointima to media wall ratio, media wall thickness, and occlusion of small pulmonary 
vessels. The neointima to media ratio was slightly decreased by treatment with 
nintedanib without statistical significance (P>0.05). Nintedanib did not demonstrate any 
effects on the media wall thickness or the occlusion of vessels, as shown in figure 29. 
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Figure 28. The effect of nintedanib on vascular remodeling in SuHx rats.  
A, neointima/media wall ratio; B, media wall thickness; C, occlusion of vessels (20-50 µm in 
diameter) from different groups, scale bars = 20µm; D, representative images for vascular 
remodeling. SuHx model was induced by Sugen5416 injection and exposure to hypoxia for three 
weeks, followed by re-exposure to normoxia for another two weeks. Control animals, which were 
injected with saline, were kept in normoxic conditions. SuHx rats were either vehicle or 50mg/kg 
nintedanib from day 21 to day 35. Control animals received vehicle only. The results are 
expressed as mean ± SEM, n=6~10 rats per group, **P<0.01. NOX, normoxia; Nin, nintedanib.   
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5 DISCUSSION 
Pulmonary arterial hypertension is characterized by excessive vasoconstriction due 
to the dysregulation of vascular tone and vascular remodeling caused by abnormal 
proliferation, migration, and resistance to apoptosis of vascular cells. Currently approved 
agents for PAH treatment are primarily vasodilators [79]. These therapeutic approaches 
relieve the pulmonary vasoconstrictive component of the disease and provide 
symptomatic relief with some improvement in prognosis. However, these is no strong 
evidence to support that these vasodilators have a direct antiproliferative effect on 
PAMSCs, and the underlying pathological pulmonary vascular and right ventricular 
remodeling still progresses.  
In this study, two antifibrotic drugs, pirfenidone and nintedanib, were administered in 
a well-recognized animal model of PAH to investigate the efficacy of these two 
compounds in the development of PAH. The novel findings of the present study are as 
follows: (1) The elevated RVSP in SuHx rats was attenuated by treatment with 
pirfenidone, but not with nintedanib. (2) Right ventricular function in SuHx rats was 
ameliorated with the treatment of pirfenidone, but not with nintedanib. Consistent with 
RV function, RV hypertrophy in the SuHx rat model was decreased by pirfenidone 
treatment, but not by nintedanib. (3) Pirfenidone inhibited the development of pulmonary 
vascular remodeling and the progression of occlusion lesions in the SuHx model, but 
nintedanib did not demonstrate the inhibitory effects on these indexes. (4) Pirfenidone 
attenuated pulmonary vascular cells proliferation and inflammation infiltration in SuHx 
rats; (5) Pirfenidone decreased collagen 1 expression by inhibiting phosphorylation of 
PDGFR-β and AKT in the lung tissue from SuHx rat. (6) Both pirfenidone and nintedanib 
reversed the proliferation of PASMCs which was induced by growth factors. (7) The 
migration of PASMCs that was induced by PDGF-BB was attenuated by both pirfenidone 
and nintedanib. (8) The collagen synthesis and secretion that was induced by PDGF-BB 
in PASMCs were inhibited by pirfenidone and nintedanib. (9) Both pirfenidone and 
nintedanib prevented the increased mRNA level of IL-1β and IL-6, which was induced by 
PDGF-BB. (10) The phosphorylation of PDGFR-β, PI3K, and AKT, which was induced 
by PDGF-BB in PASMCs, was inhibited by pirfenidone and nintedanib in vitro. 
5.1 Pirfenidone improved vascular remodeling   
 In the present study, SuHx rats were employed as a PAH model to investigate the 
efficacy of pirfenidone and nintedanib. The SuHx rat model is a relatively new animal 
model for PAH, and it is well accepted for mechanism studies and drug research and 
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development. This model demonstrates severe changes in the pulmonary vasculature 
that closely mimic the vascular changes found in patients with severe PAH. In these 
patients, two major characteristic vascular changes are medial wall thickening due to 
PASMCs proliferation, and plexiform lesions which consist of PASMCs migration and a 
hyper-proliferative endothelium [111-114]. Plexiform lesions are identified as the 
pathological hallmark of PAH from different etiologies, though classical animal models 
other than the SuHx model of PH do not show this patho-histological feature [68, 69]. 
Furthermore, the SuHx model is refractory to treatment as it is in most PAH patients, 
while with the MCT-induced PAH, it is relatively easy to improve or cure the vascular 
remodeling due to the acute or subacute nature of this model, which is not similar to 
patients with PAH [82, 115]. Therefore, SuHx rats were selected as the experimental 
PAH model for this study. 
The process of vascular remodeling is central to the pathobiology of PAH. This 
process involves structural and functional changes to the normal architecture of 
pulmonary artery (PA) walls that lead to abnormal muscularization of PAs, medical 
hypertrophy, neointima formation, and formation of plexiform lesions. This study found 
that the increased media wall thickness in the SuHx model was suppressed by 
pirfenidone. The development of occlusive lesions and neointima formation were also 
inhibited by pirfenidone. However, nintedanib failed to show beneficial effects on the 
process of vascular remodeling in SuHx model. 
Proliferation, migration, collagen deposition, and resistance to apoptosis of medial 
cells contribute to the development of vascular remodeling [116]. To explore the 
mechanism of action for pirfenidone on vascular remodeling, pulmonary artery cells 
proliferation and migration, and collagen deposition were investigated. The principal cells 
in the media of pulmonary vessels are PASMCs, and evidence shows that medial 
hypertrophy, the most consistent pathological finding in PAH, is mainly due to PASMCs 
proliferation and the remodeling of extracellular matrix (ECM) proteins [116, 117]. In this 
research, PASMCs were employed to investigate the effect of pirfenidone or nintedanib 
in these in vitro experiments. 
In addition, PDGF-BB was selected as the stimulator for PASMCs because: 1) the 
PDGF ligand and receptor and PDGF signaling are increased or upregulated in the 
patients of PAH as well as experimental PAH animals [32-36], 2) the inhibition of PDGFR 
improves the survival in MCT-induced PAH rats [36, 52], and PDGFR inhibitor imatinib 
demonstrates significant improvements in exercise capacity and hemodynamics in 
patients with advanced PAH in the IMPRES clinical phase III trial [37]. 3) In addition, 
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among the growth factors which play a role in the development of PAH, PDGF-BB is one 
of the most potent mitogens and chemoattractants for SMCs [116, 118]. Together, these 
data support the concept that PDGF and the PDGF signaling pathway are increased and 
promote pulmonary vascular remodeling in PAH. Based our experiment for effect of 
different concentration PDGF-BB on PASMCs (Figure 8), 30ng/ml was used as the 
concentration of PDGF-BB to follow experiments on PASMC proliferation and migration, 
and collagen synthesis and secretion.  
 Pirfenidone inhibited human PASMCs proliferation  
The proliferation of vascular smooth muscle cells, a prominent feature of PAH, is a 
critical event in progressive media wall thickening, which leads to vascular remodeling. 
Moreover, PCNA plays an essential role in nucleic acid replication and repair machinery, 
and is considered a marker of cell proliferation. Pulmonary artery cells proliferation was 
measured by PCNA staining. There were less PCNA positive pulmonary vessel cells 
found in the pirfenidone-treated rats than in the vehicle-treated rats due to pirfenidone's 
inhibition of proliferation. To confirm the proliferative inhibitory effect of pirfenidone on 
pulmonary artery cell proliferation, PASMCs proliferation induced by growth factors was 
employed. Similar to in vivo results, pirfenidone demonstrated a dose-response inhibitory 
effect on PAMSCs proliferation, which was induced by PDGF-BB. The high dose of 
pirfenidone (1mg/ml) even prevented the PASMCs proliferation that was induced by 
multiple growth factors. The previous study of pirfenidone discovered that pirfenidone 
could inhibit the proliferation of many different cells, including lung fibroblasts [119], 
leiomyoma cells [120], pterygium fibroblasts [121], renal fibroblasts [122], cardiac 
fibroblasts [123], hepatic stellate cells [124] and lens epithelial cells [125]. This is the first 
time that pirfenidone was shown to inhibit the proliferation of PASMCs.  
The mechanism that pirfenidone uses to inhibit DNA synthesis and cell proliferation 
is still not clear, but it does not relate to cytotoxic effects on the cells [120] because the 
cytotoxicity by was determined with a WST-1 assay, and no cytotoxic effect of 
pirfenidone was detected.   
 Pirfenidone attenuated PASMCs migration 
Migration plays an important role in physiologic processes including wound healing 
and immune function [126], and it contributes to disease processes such as inflammation 
[127], tumor growth, and metastasis [128]. Since the migration of PASMCs occurs during 
the processes of development, vascular injury, and vascular remodeling, it is possible 
that PASMCs migration plays a role in the abnormal muscularization of distal pulmonary 
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arteries, neointima formation, and the formation of plexiform lesions [114]. A recent study 
clarified the role of PASMCs proliferation and migration in neointima formation [129, 130]. 
As shown in figure 10, the increased migration that was induced by PDGF-BB was 
attenuated by the high concentration of pirfenidone. This result is consistent with the in 
vivo data showing that increased neointima was inhibited by pirfenidone treatment and 
that the occlusion of vessels decreased. 
 Pirfenidone decreased the deposition of collagen  
Thickening of the PA wall is not only the result of PASMCs proliferation, as it is also 
due to extracellular matrix (ECM) production and collagen deposition. In Wanli’s 
research, they found a PDGF-activated TGF-β1 signaling pathway in PASMCs, which 
led to the phosphorylation of Smad2/3 and an increase in collagen synthesis [108]. The 
present in vitro study shows that pirfenidone attenuated the PDGF-BB-induced collagen 
synthesis and secretion of PASMCs. The in vivo study also showed that the mRNA and 
protein level of collagen in lung tissue increased in the SuHx rat model, and both mRNA 
and protein expression decreased after treatment with pirfenidone. Although the exact 
mechanism of pirfenidone for IPF treatment is not yet clear, the antifibrotic activity is like 
achieved via suppression of TGF-β[87]. A recent investigation found that pirfenidone 
suppressed the mRNA expression of collagen and inhibited the activation of TGF-β-
related Smad pathways both in vitro (fibroblasts and retinal pigment epithelial cells) and 
in vivo [131, 132]. It is assumed that pirfenidone inhibited the signaling pathway of TGF-
β/Smad to suppress the collagen synthesis and deposition in the SuHx model by 
attenuating the phosphorylation of PDGFRβ to decrease the activity of the TGF-β1 
signaling pathway (Figure 21). 
5.2 Pirfenidone decreased right ventricle systolic pressure 
Pulmonary artery pressure (PAP) is the product of cardiac output (CO) and pulmonary 
vascular resistance. The biggest determinant of pulmonary vascular resistance is 
abnormal vascular remodeling in the small pulmonary arterioles [17]. This abnormal 
vascular remodeling includes medial hypertrophy, intima hyperplasia, and the occlusion 
of small vessels which reduces the luminal area of the small pulmonary arteries and 
results in vascular pulmonary resistance. Through the coupling of pulmonary artery 
pressure with the structural changes in the pulmonary vascular wall, and decreased 
vascular remodeling by pirfenidone treatment, pirfenidone significantly reduced RVSP in 
SuHx rats. RVSP is almost equivalent to PAP in ideal conditions.   
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Research shows that RhoA/Rho-kinase-mediated vasoconstriction is the main cause 
of persistent PAP elevation [133, 134]. Fasudil, the Rho kinase inhibitor, improved 
hemodynamics by reducing pulmonary vascular resistance and mean PAP in the 
experimental model of PAH and in patients with PAH [135-137]. Furthermore, both 
pirfenidone and fasudil demonstrated an inhibitory effect on the RhoA/Rho pathway in 
the human retinal pigment epithelial cell line, ARPE-19 [138]. The reduction of RVSP in 
the present investigation may be not only due to improvement in pulmonary vascular 
remodeling, might be also associate with a reduction in pulmonary vascular 
vasoconstriction by inhibiting the RhoA/Rho pathway. However, this requires further 
investigation. 
5.3 Pirfenidone improved right ventricle function and hypertrophy  
Sustained elevated pressure has a devastating effect on the right ventricle, as PH 
provides an excessive burden on the right ventricle from the increased work to overcome 
the elevated downstream pressure. Over time, this results in right ventricle hypertrophy, 
right ventricle dysfunction, and right-sided heart failure consecutively [112]. Right 
ventricle failure is a major cause of dysfunction or death in patients with PAH. In addition, 
right ventricle function is the most important determining index of the prognosis of PAH, 
although the main pathology is vascular remodeling in the pulmonary vasculature.    
In line with the result of the reduction in RVSP and improvement in pulmonary 
vascular remodeling, the right ventricle function also improved. Stroke volume, CO, and 
CI all significantly increased after treatment with pirfenidone compared to the vehicle. In 
this study, pirfenidone reduced right ventricle hypertrophy; this was demonstrated by 
decreased right ventricle internal diameter and the Fulton index, which are the markers 
of right ventricle hypertrophy. These data show that right ventricle hypertrophy was 
attenuated along with the improvement of right ventricle function after the reduction of 
right ventricle systolic pressure by pirfenidone treatment.   
5.4 Pirfenidone suppressed expression of inflammatory markers  
Inflammation underlies a wide variety of physiological and pathological processes. 
Increasing evidence indicates that inflammation is a major pathogenic component of 
vascular remodeling. Inflammatory processes are involved in the initiation and 
development of human PAH as well as in experimental models of PAH. Tuder’s 
investigation found that an increased number of macrophages are present in the 
plexiform lesion of the patients with PAH [68], and in the chronic hypoxia and MCT- 
induced PH animal models [139, 140]. In addition, macrophage infiltration and activation 
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may induce the release of IL-1β, IL-6, monocyte chemotactic protein-1 (MCP-1), and 
TNF-α, which all play an important role in the pathogenesis of PAH [71, 141]. In the 
present study, macrophage (CD68 positive cells) accumulation was identified in the 
pulmonary vessels of the SuHx model rats. This study also demonstrates that the mRNA 
level of IL-1β and IL-6 are significantly elevated in SuHx lung tissue and in PASMCs after 
PDGF-BB stimulation.  
Pirfenidone was initially designed as an anti-inflammatory agent, though the focus 
was later shifted to an anti-fibrotic agent [87]. Pirfenidone can modulate the expression 
of proinflammatory cytokines in addition to the effect of inhibiting pro-fibrotic factors [87]. 
The anti-inflammatory activity of pirfenidone has been demonstrated in a septic shock 
model [142] and a bleomycin-induced lung fibrosis model in mice [143]. Moreover, 
pirfenidone suppressed the production of TNF-α by post-transcriptional regulation of the 
TNF-α gene and enhanced the production of IL-10 in this septic shock mice model [142]. 
The proinflammatory cytokines in the lung tissue, such as IL-1β, IL-6, and MCP-1, were 
all inhibited by pirfenidone in this bleomycin-induced lung fibrosis model [143]. In 
addition, Gurujeyalakshmi reported that pirfenidone suppressed the mRNA level of 
PDGF-A and PDGF-B in bleomycin-induced lung fibrosis in hamsters [144]. This present 
study demonstrated that pirfenidone inhibited macrophage infiltration and accumulation. 
Consistent with the previous study on the effect of pirfenidone on inflammation, IL-1β 
and IL-6 mRNA expression was suppressed by pirfenidone in the lung tissue of SuHx 
rats and in PASMCs after PDGF-BB stimulation. The effect of pirfenidone on vascular 
remodeling is at least partly through inhibiting the inflammatory activity to achieve. 
5.5 Pirfenidone inhibited PDGFRβ-PI3K-AKT signaling pathway 
Growth factors, including PDGF [32, 36], EGF [60], and VEGF [145], have been 
implicated in the abnormal proliferation and migration of pulmonary artery vascular cells 
during vascular remodeling in patients with PAH and in experimental animal models of 
PAH. These growth factors act as potent mitogens and chemoattractants for SMCs, 
fibroblasts, and ECs by binding to receptor tyrosine kinases (RTKs) as extracellular 
stimuli to stimulate several intracellular signaling pathways including MAP kinase, protein 
kinase C, Rho/Rho A kinase, and phosphoinositide 3-kinase (PI3K) /Akt pathway [146]. 
The PI3K/Akt signaling pathway acts an important role in vascular development and 
normal vascular function.  
PI3K is a heterodimeric enzyme that consists of one 85-kDa regulatory subunit and 
one 110-kDa catalytic subunit [147] and acts as a major signaling pathway component 
downstream of RTKs [148, 149]. PI3K catalyzes the production of phosphatidylinositol-
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3, 4, 5-triphosphate, which activates essential downstream targets, such as 
serine/threonine kinase Akt [150]. The PI3K-Akt pathway regulates multiple cellular 
processes, including cell proliferation, migration, growth, and survival [149]. Although 
PI3K is well characterized as a major regulator of Akt activation in response to a variety 
of ligands, recent studies have found a diverse group of tyrosine and serine/threonine 
kinases that activate Akt directly to promote its pro-proliferative signaling functions [151, 
152].  
The importance of PI3K/Akt signaling in normal vascular development is exemplified 
by gene knockout studies. Mice models have an endothelial-specific knockdown of 
phosphatase and a tensin homolog (PTEN), and an inhibitor of PI3K/Akt; they exhibit 
increased angiogenesis [153]. Akt-1 gene knockout mice demonstrate delayed vessel 
maturation and increased vascular permeability [154].   
In addition to the important role in normal vascular development and function, the 
PI3K/Akt pathway participates in vascular remodeling and the development of various 
vascular pathologies. Goncharova’s study showed that PDGF-BB stimulates PASMCs 
proliferation and migration by activating the PI3K/Akt signaling cascade, demonstrating 
that PI3K/Akt signaling is both necessary and sufficient to mediate human pulmonary 
vessel SMCs proliferation and migration [155]. Furgeson et al. demonstrated that the 
inactivation of PTEN in SMCs promotes a pro-inflammatory phenotype and enhances 
neointima formation [156]. Both the inhibitors of PI3K and Akt attenuated hypoxia-
induced pulmonary artery remodeling in rats. However, the Akt inhibitor triciribine 
blocked all manifestations of PH in vivo except elevated PAP, whereas PI3K inhibitor 
LY294002 alone suppressed a subset of endpoints [157]. The author speculated that 
this finding may be due to an Akt-independent pathway [157]. However, other 
investigations found that the PI3K inhibitor wortmannin [158] and Akt1 [159] knockout 
inhibited pulmonary vascular remodeling and decreased PAP by involving a PI3K/Akt 
signaling hypoxia-induced PAH animal model. In the present study, pirfenidone 
abolished the phosphorylation of Akt and PDGFRβ that was activated in SuHx rats. In 
addition, the in vitro data show that phosphorylation of PDGFRβ, PI3K, and Akt that was 
induced by PDGF-BB were all inhibited by pirfenidone. It is possible that the effect of 
pirfenidone on hemodynamics and vascular structure changes partly due to the inhibition 
of PI3K/Akt signaling cascade. 
Previous studies from our lab have found that PFDGFR inhibitor imatinib reverses 
pulmonary hemodynamics and structural changes of the pulmonary artery in the animal 
model of PAH. Clinical trials also show that imatinib improves hemodynamics in patients 
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with PAH. Based on these data that pirfenidone inhibited PDGFRβ phosphorylation in 
vitro and in vivo, the inhibition of the PDGFRβ pathway is another mechanism of action 
for the efficacy of pirfenidone.  
5.6 The effects of nintedanib on SuHx rats  
Nintedanib demonstrated a potent inhibitory effect on PASMCs proliferation and 
migration induced by PDGF-BB. The PDGF-BB-induced collagen synthesis and 
secretion was also reversed by nintedanib. Furthermore, in vitro data shows that 
nintedanib inhibited inflammation and reversed the phosphorylation of PDGFRβ, PI3K, 
and Akt. Nintedanib seems to have a strong potent inhibitory effect compared to 
pirfenidone according to the in vitro data from this present investigation.  
Nintedanib is an inhibitor of the receptor tyrosine kinases PDGFR-α/β with half 
maximal inhibitory concentration (IC50) values of 59 and 65 nmol/L[101],  and the IC50 for 
imatinib on PDGFR is in the range of 100nmol/L[160]. According to the available data, 
imatinib improved hemodynamics and vascular remodeling by regulating PDGF 
signaling. Nintedanib was expected to have similar effects and be a novel therapeutic 
approach for the patients with PAH. However, nintedanib did not demonstrate any effect 
on hemodynamics; there was a tendency to decrease vascular remodeling, but no 
statistical significance was achieved by nintedanib treatment.   
Dasatinib, another TKI, demonstrated potent inhibition of PDGF-induced responses 
in vascular SMC [161]. However, clinical reports show that dasatinib induces severe 
precapillary PH fulfilling the criteria of PAH during dasatinib treatment for chronic myeloid 
leukemia (CML), and dasatinib induced PAH was completely resolved or partially 
reversed after withdrawal of TKI [162-164]. There are several hypotheses about the 
opposite effect of dasatinib and imatinib on PAH. Dumitrescu et al. speculated that Src 
inhibition may play a role in the development of dasatinib-associated PAH, because the 
main known difference in the kinase profile between dasatinib and imatinib is the 
additional inhibition of Src family kinases. Dasatinib inhibits PDGF-induced proliferation 
and the migration of vascular smooth muscle cells by inhibiting PDGFR activity and 
PDGF-dependent Src activation downstream of the PDGFR [161], which is beneficial in 
PAH. However, Src family kinases are required for the degradation of activated PDGFRs 
[165]. Thus, inhibition of Src might lead to increased signaling by PDGF.  
An additional explanation may be related to off-target kinase inhibition. These 
mechanisms may influence pulmonary vascular wall integrity, leading to (peri)-vascular 
edema and increased PVR [163]. David et al. have similar views on dasatinib-associated 
PAH, which may due to the less specific target profile of dasatinib compared to imatinib, 
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allowing the additional inhibition of  Src and Eph receptor[162, 166]. Nintedanib also 
inhibits nonreceptor tyrosine kinases of the Src family with IC50 values of 156 nmol/L for 
Src, 16 nmol/L for Lck, and 195 nmol/L for Lyn [101]. Therefore, the benefits of nintedanib 
on PAH through the inhibition PDGF signaling may be abolished by the suppression of 
the Src pathway or off-target kinase inhibition.  
A recent investigation found elevations in markers of endothelial dysfunction and 
vascular damage in the serum of CML patients treated with dasatinib, when compared 
with CML patients treated with imatinib [167]. This investigation showed that dasatinib 
treatment causes pulmonary EC dysfunction in vivo and in vitro, and induces apoptosis 
in cultured human pulmonary ECs through mitochondrial ROS production, independent 
of its action on Src family kinases. The pretreatment of rats with dasatinib exaggerates 
the response to MCT administration and exposure to chronic hypoxia, which are two 
inducers of pulmonary vascular remodeling. It is believed that increased susceptibility to 
PAH development is due to pulmonary vascular damage, induction of endoplasmic 
reticulum stress, and mitochondrial ROS production caused by dasatinib.  
The previous study demonstrated that nintedanib induced apoptosis in human 
umbilical vascular endothelial cells, human umbilical artery smooth muscle cells, and 
bovine retinal pericytes [101]. It was expected that nintedanib may also induce apoptosis 
in PASMCs and vascular endothelial cells, which might counteract the inhibition of PDGF 
signaling to cancel out the therapeutic benefits of nintedanib on PAH. Furthermore, the 
VEGF receptor 2 blockade (subcutaneous injection of Su5416 with IC50 1.23µmol/L) is 
the ‘first hit’ that causes lung vascular endothelial cell apoptosis, and chronic hypoxia 
acts as the ‘second hit’ in this SuHx model. Nintedanib is an inhibitor of VEGFR subtypes 
with an IC50 of 13-34nmol/L. Theoretically, nintedanib can also be a harmful ‘hit’ by 
inducing vascular endothelial cells apoptosis to initiate the development of PAH. 
However, the role of VEGF is complex and inconsistent in pre-clinical data, and sorafenib 
attenuates the development of experimental PH (in both MCT and SuHx model) by 
inhibition of VEGF signaling [52, 53]. Since VEGF signaling plays a complex role in 
pulmonary pathophysiology, whether nintedanib can induce apoptosis in PASMCs or 
ECs via VEGF signaling is currently unknown and further study is required.  
5.7 Limitations of this study   
All three layers of the vessel wall are involved in the process of vascular remodeling. 
In addition to PASMCs, endothelial cells, fibroblasts, inflammatory cells, and platelets 
also play significant roles in PAH [111]. For example, EC apoptosis has been implicated 
as an initiating event in experimental PAH, leading either directly to the degeneration of 
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pre-capillary arterioles or to the selection of hyperproliferative, apoptosis-resistant, 
endothelial cells that may contribute to angioproliferative plexiform lesions. This study 
focused on PASMCs, and the effects of pirfenidone on ECs and other types of cells 
should be investigated in future experiments.  
The net balance between apoptosis and proliferation determines the growth of 
PASMCs. Furthermore, the inhibition of apoptosis in PASMCs is involved in the 
development and progression of pulmonary arterial medial hypertrophy [168]. The effect 
of pirfenidone on the induction and enhancement of PASMCs apoptosis was not 
investigated. Previous studies of pirfenidone have either demonstrated no effect on 
apoptosis [132] or reduced apoptosis [89, 169]. Pirfenidone probably would not increase 
apoptosis to against the apoptosis-resistant phenomenon during the vascular 
remodeling process, which is required future research to investigate. 
 Since nintedanib did not show efficacy in RVSP, RV function, hypertrophy, or 
vascular remodeling in the SuHx rat model, further in vivo study of nintedanib on 
inflammation, collagen expression, and vascular proliferation was not performed 
although nintedanib demonstrated potent effects on PASMCs proliferation, migration, 
and other functional processes that were induced by PDGF-BB in vitro. The effect of 
nintedanib on EC apoptosis and the consequence of Src inhibition were not investigated, 
which may be a reason against benefits from inhibition PDGF signaling pathway.      
5.8 Conclusion 
In summary, this is the first paper to describe the successful therapeutic use of 
pirfenidone in a well-accepted animal model of PAH. Pirfenidone significantly attenuated 
PAP and vascular remodeling, and effectively improved RV function and RV hypertrophy. 
Although the key target molecule for pirfenidone is not yet clear and further research is 
needed to elucidate its precise mechanism of action, pirfenidone appears to exert 
inhibitory effects on multiple pathways that lead to the development of PAH. The 
multifunctional activity of pirfenidone includes suppression of inflammation, proliferation, 
migration, and collagen deposition of PASMCs by acting on the PDGF and PI3K/Akt 
signaling cascade. Pirfenidone has been prescribed to IPF patients since 2008 and has 
been well tolerated without severe side effects, and its clinical development as a new 
indication for PAH and PH due to lung disease through vascular remodeling might be 
imminent. 
PDGF-BB-induced PASMCs proliferation, migration, and inflammation, and collagen 
synthesis and phosphorylation of PDGF/PI3K/Akt signaling were inhibited or reversed 
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by nintedanib in an in vitro study. Nintedanib demonstrated potent inhibitory effects on 
the PDGF signaling pathway, but did not show therapeutic effects on the SuHx rat model.  
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6 Summary 
Pulmonary hypertension, defined by an mPAP of 25 mm Hg or more at rest, is a 
severe, progressive disease with no cure. In addition, PAH is characterized by an 
angioproliferative vasculopathy, mainly in the small pulmonary arteries, which results in 
progressive pulmonary vascular remodeling, increased pulmonary vascular resistance, 
and right ventricle dysfunction and failure. The proliferation, migration, and collagen 
synthesis of PASMCs play critical roles in pulmonary vascular remodeling. 
Current pharmacotherapies that are approved for PAH treatment are focused on 
vasodilators. These therapeutic approaches relieve the pulmonary vasoconstrictive 
component of the disease and provide symptomatic relief with some amelioration in the 
prognosis. However, there is no strong evidence supporting that these vasodilators have 
a direct antiproliferative effect on PAMSCs, and the underlying pathological pulmonary 
vessels and right ventricle remodeling still progress. Therefore, future medical 
intervention strategies must go beyond vasodilation, for the medicine targeting vascular 
remodeling processes in pulmonary vasculature to have great potential therapeutic value 
and a promising future. 
Both pirfenidone and nintedanib were approved for treatment IPF in 2014 by the FDA, 
ending an era without effective pharmacologic therapy for IPF. Based on the antifibrotic 
effect of pirfenidone and nintedanib in experimental pulmonary fibrosis and IPF patients, 
it was hypothesized that pirfenidone may inhibit collagen synthesis and the cell 
proliferation of PASMCs induced by growth factors in PH. Thus, the effects of pirfenidone 
and nintedanib on proliferation, migration, collagen synthesis, and inflammation in vitro 
were investigated. The efficacy of pirfenidone and nintedanib on hemodynamics and 
pulmonary vascular remodeling were also investigated in a PAH animal model.  
An in vitro cellular study showed that both pirfenidone and nintedanib inhibited 
proliferation, migration, inflammation, collagen synthesis, and collagen secretion that 
was induced by PDGF. The PDGF-induced phosphorylation of PDGFR/PI3K/Akt 
signaling was also inhibited by these two compounds.  
Given the promising in vitro effects, an experimental PAH rat model (SuHx) induced 
by a Sugen5416 injection and three weeks of hypoxia exposure was employed to 
evaluate the efficacy of pirfenidone and nintedanib in vivo. Pirfenidone treatment 
decreased the elevated RVSP, improved impaired RV function, and inhibited RV 
hypertrophy in SuHx rats. The pulmonary vascular remodeling in SuHx rats was also 
ameliorated after treatment with pirfenidone. To explore the mechanism of action for 
pirfenidone on vascular remodeling, vascular cells proliferation, collagen deposition, and 
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inflammation were investigated. Pirfenidone decreased vascular cells proliferation and 
collagen deposition, and suppressed inflammation by inhibiting phosphorylation of the 
PDGFR/Akt pathway. However, nintedanib did not demonstrate therapeutic effects on 
vascular remodeling, RVSP, RV function, or hypertrophy in the SuHx model. 
In summary, this is the first paper to describe the successful therapeutic use of 
pirfenidone in a well-accepted animal model of PAH. Pirfenidone significantly attenuated 
PAH and the vascular remodeling, and effectively improved RV function and RV 
hypertrophy. Pirfenidone appears to exert inhibitory effects on multiple pathways that 
lead to the development of PAH, which includes the suppression of inflammation, 
proliferation, migration, and collagen deposition of PASMCs by acting on PDGF and the 
PI3K/Akt signaling cascade. The clinical development of pirfenidone as a new indication 
for PAH and PH due to lung disease through the improvement of vascular remodeling 
might be imminent. Nintedanib demonstrated potent inhibitory effects on cellular function 
in vitro, but did not show therapeutic effects in the SuHx rat model. 
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7 ZUSAMMENFASSUNG 
De Lungenhochdruck (PAH) ist eine schwere, fortschreitende Erkrankung ohne 
Aussicht auf Heilung. PAH ist charakteriziert durch eine überwiegend in den kleinen 
Lungenarterien ablaufende angioproliferative Vaskulopathie, welche zu fortschreitenden 
Lungengefäßumbauprozessen, gesteigertem Lungengefäßwiderstand gefolgt von einer 
rechten Kammerdysfunktion und Kammerversagen, führt. Die Proliferation, Migration 
und Kollagensezernierung von glatten pulmonalen arteriellen Muskelzellen (PASMCs) 
spielen eine entscheidende Rolle in den Umbauprozessen der Pulmonalarterie. 
Aktuelle Pharmakotherapien, welche für die PAH zugelassen sind, greifen auf der 
Grundlage der Gefäßerweiterung. Diese therapeutischen Ansätze vermindern die 
vasokonstriktive Komponente der Krankheit und führen zu einer Symptomlinderung 
sowie einer kleinen Prognoseverbesserung. Nichtsdestotrotz gibt es keine 
aussagekräftigen Anhaltspunkte, welche die Vasoldilatatoren im Hinblick auf einen 
direkten antiproliferativen Effekt auf PASMCs unterstützen und der zugrunde liegende 
pathologische Gefäßwandumbau und rechter Ventrikelumbau schreitet weiter voran. 
Deswegen müssen zukünftige medikamentöse Therapien über Vasodilatatoren 
hinausgehen, und Medikamente, welche in die Umbauprozesse der Lungengefäße 
eingreifen, haben eine potentiell großen Wert und eine vielversprechende Zukunft. 
Pirfenidone und Nintedanib sind beide für die Behandlung der idiopathischen 
Lungenfibrose durch die FDA 2014 zugelassen worden, welches damit das Ende des 
Zeitalters einer fehlenden effektiven Pharmakotherapie der IPF eingeleitet hat. Auf dem 
antifbrotischen Effekt von Pirfenidone und Nintedanib in experimenteller Lungenfibrose 
und IPF Patienten zurückführend, wurde die Hypothese aufgestellt, dass Pirfenidone die 
Kollagensynthese und Zellproliferation von PASMCs, welche durch Wachstumsfaktoren 
bei Lungenhochdruck induziert werden, hemmt. Daher wurde untersucht inwieweit 
Pirfenidone und Nintedanib die Proliferation, Migration Kollagensynthese und 
Entzündung in vitro beeinflussen würden. Weiterhin wurde die Wirksamkeit von 
Pirfenidone/Nintedanib auf die Hämodynamik und die Umbauprozess der Lungengefäße 
in einem PAH Tiermodell überprüft. 
In vitro Experimente zeigten, dass sowohl Pirfenidone als auch Nintedanib die PDGF 
induzierte Proliferation von PASMCs hemmen. Beide Substanzen hemmen auch die 
Migration, Entzündung, Kollagensynthese und Kollagensezernierung der PASMCs, 
welche durch PDGF induziert wurde. Zusätzlich wurde die durch PDGF bedingte 
Phosphorylierung  von PDGFRβ/PI3K/AKT ebenfalls durch beide Substanzen blockiert. 
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Im Zuge dieser vielversprechenden in vitro Effekte, wurde ein experimentelles PAH 
Rattenmodell (SuHx) angewendet, welches durch die Injektion von Sugen 5416, in 
Kombination mit 3 Wochen Hypoxie, induziert wurde um die Wirksamkeit von Pirfenidone 
und Nintedanib in vivo zu erproben. Die Behandlung mit Pirfenidone verminderte den 
erhöhten rechtsventrikulären systolischen Druck, verbesserte die beeinträchtigte RV 
Funktion und hemmte die RV-Hypertrophie in SuHx Ratten. Die Umbauprozesse der 
Lungengefäße in den SuHx Ratten wurde ebenfalls verbessert. Um den genauen 
Mechanismus von Pirfenidone auf den positiven Effekt bezüglich der 
Gefäßumbauprozesse zu untersuchen, wurde der Einfluss von Pirfenidone auf die 
Gefässzellen im Hinblick auf Proliferation, Kollagensezernierung und Entzündung in der 
Lunge überprüft. Pirfenidone verminderte die Zellproliferation, Kollagensezernierung und 
unterdrückte Entzündungserscheinungen durch die Hemmung der Phosphorylierung im 
PDGFRβ/Akt Signalweg. Nintedanib jedoch zeigte keinen therapeutischen Wert 
hinsichtlich der Gefäßumbauprozesse, RVSP, RV Funktion und Hypertrophie im SuHx 
Modell. 
Schlussfolgernd lässt sich nun also sagen, dass erstmalig der erfolgreiche 
therapeutische Nutzen von Pirfenidone in einem gut akzeptierten Tiermodel der PAH 
beschrieben werden konnte. Pirfenidone verbessert signifikant den arteriellen 
Lungenhochdruck und die Gefäßumbauprozesse, verbessert die RV-Funktion sowie RV-
Hypertrophie. Pirfenidone scheint inhibierende Wirkungen auf verschieden Signalwege, 
welche zur Entwicklung von PAH führen, welche die Unterdrückung von Entzündung, 
Proliferation, Migration und Kollagensezernierung beinhaltet, in dem es auf die PDGF 
und PI3k/Akt Signalkaskade wirkt, zu haben. Die klinische Entwicklung von Pirfenidone 
als ein neues Mittel für arteriellen Lungenhochdruck oder Lungenhochdruck welches auf 
Lungenerkrankungen zurückzuführen ist, könnte nun also bevorstehen. Nintedanib 
zeigte hemmende Effekte auf die zelluläre Funktion in vitro aber keine therapeutischen 
Effekte im SuHx Ratten Modell.              
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11 Abbreviation 
AC: adenylyl cyclase 
ALK1: activin receptor-like kinase 1 
APS: ammonium persulfate  
ATP: adenosine triphosphate  
BH2: dihydrobiopterin  
BH4: tetrahydrobiopterin   
BMPR2: bone morphogenic protein receptor type II 
BSA: bovine serum albumin  
CAV1: caveolin-1 
CD68: cluster of differentiation 68 
cDNA: complementary deoxyribonucleic acid 
cGMP: guanosine 3’,5’-monophosphate   
CI: Cardiac index   
CML: chronic myeloid leukemia  
CO: Cardiac output  
COX: cyclooxygenase 
Ct: threshold cycle 
CTEPH: chronic thromboembolic pulmonary hypertension  
Da: dalton 
DAPI: 4', 6-diamidino-2-phenylindole  
DMSO: Dimethyl sulfoxide   
DPBS: Dulbecco's Phosphate-Buffered Saline 
EC: endothelial cell  
ECEs: endothelin-converting enzymes 
ECG: Electrocardiography 
ECL: Enhanced chemiluminescence    
ECM: extracellular matrix 
EDTA: Ethylenediaminetetraacetic acid   
EGF: epidermal growth factor  
endo-MT: endothelial mesenchymal transition   
ENG: endoglin 
eNOS: endothelial NO synthase enzyme  
ET-1: endothelin-1  
ETA: endothelin receptor type A  
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et al.: et alii (and others) 
ETB: endothelin receptor type B 
FAK: focal adhesion kinase 
FDA: Food and Drug Administration 
FGF: fibroblast growth factor ` 
FGFR-1: fibroblast growth factor receptor-1   
FLT3: Fms-like tyrosine kinase-3 
FRS2: FGFR substrate 2 
g: gram 
GTP: guanosine 5’-triphosphate   
Grb2: growth factor receptor-bound protein 2 
Hg: hydrargyrum 
HGF: hepatocyte growth factor  
HIV: human immunodeficiency virus 
HRP: horse radish peroxidase 
HSP: heat shock protein 
IFN: interferon    
IPAH: idiopathic pulmonary arterial hypertension 
IPF: idiopathic pulmonary fibrosis  
kb: kilo base  
KCNK3: potassium channel, two pore domain subfamily K, member 3  
KCl: Potassium chloride   
kDa: kilo dalton 
KH2PO4M: monopotassium phosphate  
IC50: maximal inhibitory concentration   
IL-1: interleukin-1   
IL-1β: interleukin-1β  
IL-6: interleukin-6   
i.m.: intramuscular   
i.p.: intraperitoneal   
M: molar (mole/litre) 
MEK1/2: mitogen-activated protein kinase kinase 1/2  
MCP: monocyte chemoattractant protein  
MCT: monocrotaline-treated 
min: minute(s) 
ABBREVIATION 
87 
 
miRNA: microRNA 
mg: milligram 
ml: milliliter 
mm: millimeter 
mM: millimolar 
mPA:  mean pulmonary artery pressure  
Na2HPO4: disodium phosphate   
NaCl: sodium chloride   
NADPH: nicotinamide adenine dinucleotide phosphate   
nm: nanometer 
nM: nanomolar 
NO: nitric oxide  
NOX: normoxia 
nRTKs: non-receptor tyrosine kinases   
PAH: pulmonary arterial hypertension  
PAP: pulmonary artery pressure  
PASMCs: pulmonary artery smooth muscle cells  
PAWP: pulmonary artery wedge pressure  
PBS: phosphate-buffered saline  
PCNA: Proliferating Cell Nuclear Antigen 
PCR: polymerase chain reaction 
PDE5: phosphodiesterase 5 
PDGF: platelet derived growth factor 
PDGFR: platelet derived growth factor receptor 
PFA: paraformaldehyde   
PH: pulmonary hypertension   
PI3K: phosphatidylinositol-4,5-bisphosphate 3-kinase 
PIP2/3: phosphatidylinositol-2/3-phosphate 
PKA: protein kinase A  
PKC: protein kinase C 
PKG: protein kinase G   
PLC-γ: phospholipase C-γ 
PPARs: peroxisome proliferator-activated receptors  
PTEN: phosphatase and tensin homolog   
PVR: pulmonary vascular resistance   
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qRT-PCR: quantitative real-time polymerase chain reaction   
RIPA: radio immunoprecipitation assay 
RNA: ribonucleic acid 
ROS: reactive oxygen species 
rpm: revolution per minute 
RT: room temperature 
RVSP: right ventricular systolic pressure   
RVID: right ventricle internal diameter  
SDS-PAGE: SDS-polyacrylamide gel electrophoresis   
sGC: soluble guanylyl cyclase   
SM: smooth muscle  
SMAD: mothers against decapentaplegic homolog 
SmBM: smooth muscle basal medium  
SMC: smooth muscle cell 
SmGM-2: smooth muscle growth medium-2  
SOS: son of sevenless 
SV: stroke volume   
TBST: Tris-buffered saline and Tween 20 
TEMED: tetramethylethylenediamine   
TGF-α: transforming growth factor alpha   
TGFβ: transforming growth factor β  
TKR: tyrosine kinase receptors   
TNF: tumor necrosis factor    
V: volt 
VEGF: vascular endothelial growth factor 
VEGFR2: vascular endothelial growth factor receptor 2   
WU: Wood units  
μg: microgram 
μl: microliter 
μm: micrometer 
μM: micromolar 
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